fluconazole has been researched along with HIV Coinfection in 299 studies
Fluconazole: Triazole antifungal agent that is used to treat oropharyngeal CANDIDIASIS and cryptococcal MENINGITIS in AIDS.
fluconazole : A member of the class of triazoles that is propan-2-ol substituted at position 1 and 3 by 1H-1,2,4-triazol-1-yl groups and at position 2 by a 2,4-difluorophenyl group. It is an antifungal drug used for the treatment of mucosal candidiasis and for systemic infections including systemic candidiasis, coccidioidomycosis, and cryptococcosis.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A total of 245 patients (age, > or =18 years) with a prior diagnosis of acquired immunodeficiency syndrome/human immunodeficiency virus (HIV) infection and esophageal candidiasis, confirmed by endoscopy and culture, were randomized to receive micafungin (50, 100, or 150 mg per day) or fluconazole (200 mg per day)." | 9.11 | A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients. ( Baraldi, E; de Wet, N; Della Negra, M; Diekmann-Berndt, H; Krantz, EF; Llanos-Cuentas, A; Suleiman, J, 2004) |
| " During 2-year follow-up, there were no differences of survival rates and occurrences of newly diagnosed cryptococcosis between patients with and without fluconazole for primary prophylaxis of cryptococcosis." | 7.85 | Primary Prophylaxis for Cryptococcosis With Fluconazole in Human Immunodeficiency Virus-Infected Patients With CD4 T-Cell Counts <100 Cells/µL and Receiving Antiretroviral Therapy. ( Pattanapongpaiboon, W; Savetamornkul, C; Sungkanuparph, S, 2017) |
| "A 52-year-old man with well-controlled HIV infection taking ritonavir and increasing doses of inhaled fluticasone for chronic bronchitis developed thrush." | 7.78 | Role of fluconazole in a case of rapid onset ritonavir and inhaled fluticasone-associated secondary adrenal insufficiency. ( Maguire, JD; St Clair, K, 2012) |
| "We report on the correlation of the outcomes for two cohorts of patients who had been treated for candidemia (126 episodes) or oropharyngeal candidiasis (110 episodes) with various doses of fluconazole and the MIC of fluconazole obtained by using the EUCAST standard for fermentative yeasts." | 7.74 | Correlation of the MIC and dose/MIC ratio of fluconazole to the therapeutic response of patients with mucosal candidiasis and candidemia. ( Almirante, B; Cuenca-Estrella, M; Donnelly, JP; Laguna, F; Mouton, JW; Pahissa, A; Rodríguez-Pardo, D; Rodríguez-Tudela, JL, 2007) |
| "This study aimed to test the MICs (minimal inhibitory concentrations) to fluconazole of Candida species isolated from mouthwash specimens of 54 HIV positive patients with oral candidiasis." | 7.71 | Clinical and mycological responses to fluconazole and fluconazole MIC in oropharyngeal candidiasis in HIV-infected patients. ( Bussaratid, V; Howe, P; Phonrat, B; Pitisuttithum, P; Simpson, A; Tansupasawasdikul, S; White, NJ, 2002) |
| "We have reviewed the efficacy of the use of fluconazole in patients with definitely proven Candida esophagitis (CE) associated with human immunodeficiency virus (HIV) infection, using a single 400 mg oral dose of fluconazole and evaluating the patient three days afterwards." | 7.68 | [Candida esophagitis treated with a single dose of fluconazole in patients with HIV: presentation of 11 cases]. ( Carrasco, R; Martínez, A; Medina, E; Navarro, V; Nieto, A; Roig, P; Salavert, M, 1990) |
| "Fluconazole is a bis-triazole antifungal agent with a long serum half-life." | 6.67 | Fluconazole for oropharyngeal candidiasis in anti-HIV positive haemophiliacs. ( Hales, M; Kernoff, PB; Lee, CA; Lim, SG; O'Doherty, M; Winter, M, 1991) |
| "Fluconazole is a triazole antifungal agent which is now an established part of therapy in patients with immune deficiencies." | 6.39 | Fluconazole. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients. ( Barradell, LB; Goa, KL, 1995) |
| "Fluconazole is a new triazole antifungal agent with good activity against Candida and cryptococcal meningitis." | 6.38 | Fluconazole: a new option in the treatment of Candida mucositis and esophageal candidiasis. ( Garber, GE, 1992) |
| "The AmBisome Therapy Induction Optimization (AMBITION-cm) trial, conducted in eastern and southern Africa, showed that a single, high dose (10 mg/kg) of liposomal amphotericin B, given with an oral backbone of fluconazole and flucytosine, was noninferior to the World Health Organization (WHO)-recommended regimen of 7 days of amphotericin B deoxycholate plus flucytosine for treatment of human immunodeficiency virus (HIV)-associated cryptococcal meningitis and has been incorporated into WHO treatment guidelines." | 5.69 | How Applicable Is the Single-Dose AMBITION Regimen for Human Immunodeficiency Virus-Associated Cryptococcal Meningitis to High-Income Settings? ( Boulware, DR; Harrison, TS; Hosseinipour, MC; Jarvis, JN; Lawrence, DS; Lortholary, O; Meintjes, G; Mosepele, M; Mwandumba, HC, 2023) |
| " Fluconazole during pregnancy may be associated with spontaneous abortion and craniofacial and heart defects." | 5.22 | Vulvovaginal Candidiasis: A Review of the Evidence for the 2021 Centers for Disease Control and Prevention of Sexually Transmitted Infections Treatment Guidelines. ( Brookhart, C; Lazenby, G; Nyirjesy, P; Schwebke, J; Sobel, JD, 2022) |
| "Cryptococcal antigen screening is recommended among people living with AIDS when entering HIV care with a CD4 count of <100 cells/μl, and preemptive fluconazole monotherapy treatment is recommended for those with subclinical cryptococcal antigenemia." | 5.20 | Increased Antifungal Drug Resistance in Clinical Isolates of Cryptococcus neoformans in Uganda. ( Achan, B; Akampurira, A; Alhadab, AA; Boulware, DR; Hullsiek, KH; McDonald, TR; Meya, DB; Nielsen, K; Okagaki, LH; Rhein, JR; Smith, KD, 2015) |
| "A total of 245 patients (age, > or =18 years) with a prior diagnosis of acquired immunodeficiency syndrome/human immunodeficiency virus (HIV) infection and esophageal candidiasis, confirmed by endoscopy and culture, were randomized to receive micafungin (50, 100, or 150 mg per day) or fluconazole (200 mg per day)." | 5.11 | A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients. ( Baraldi, E; de Wet, N; Della Negra, M; Diekmann-Berndt, H; Krantz, EF; Llanos-Cuentas, A; Suleiman, J, 2004) |
| " Five were exposed to 200-800 mg fluconazole during pregnancy." | 5.05 | Cryptococcosis in pregnancy and the postpartum period: Case series and systematic review with recommendations for management. ( Boulware, DR; Evans, EE; Meya, DB; Muzoora, C; Nalintya, E; Ndyetukira, JF; Nuwagira, E; Pastick, KA; Rajasingham, R; Rhein, J; Skipper, C; Ssebambulidde, K; Stephens, N; Tugume, L, 2020) |
| "HIV-uninfected CM patients who received high-dose fluconazole (800 mg/d) for initial therapy in Huashan Hospital were included in this retrospective study from January 2013 to December 2018." | 4.31 | Induction therapy with high-dose fluconazole plus flucytosine for human immunodeficiency virus-uninfected cryptococcal meningitis patients: Feasible or not? ( Cheng, JH; Jiang, YK; Luo, Y; Wang, X; Zhao, HZ; Zhou, LH; Zhu, LP; Zhu, RS, 2023) |
| " Although fluconazole and amphotericin B are the first-line treatments for cryptococcosis, the rate of fluconazole resistance has increased significantly due to long-term use." | 4.12 | In vitro synergistic effect of minocycline combined with antifungals against Cryptococcus neoformans. ( Chen, M; Shi, H; Sun, Y; Tan, L; Wang, Z; Yao, Z, 2022) |
| " The patient was initially treated with amphotericin B deoxycholate plus fluconazole for disseminated cryptococcosis, according to guideline recommendations." | 3.91 | Invasive fungal infection by Cryptococcus neoformans var. grubii with bone marrow and meningeal involvement in a HIV-infected patient: a case report. ( Bay, MB; de Oliveira, AL; Freire, MG; Gomes, RMODS; Soares, RDA; Theodoro, RC; Vechi, HT, 2019) |
| " During 2-year follow-up, there were no differences of survival rates and occurrences of newly diagnosed cryptococcosis between patients with and without fluconazole for primary prophylaxis of cryptococcosis." | 3.85 | Primary Prophylaxis for Cryptococcosis With Fluconazole in Human Immunodeficiency Virus-Infected Patients With CD4 T-Cell Counts <100 Cells/µL and Receiving Antiretroviral Therapy. ( Pattanapongpaiboon, W; Savetamornkul, C; Sungkanuparph, S, 2017) |
| " She was then diagnosed as disseminated cryptococcosis and treated with liposomal amphotericin B and fluconazole successfully." | 3.83 | [A pediatric case of HIV who diagnosed by virtue of disseminated cryptococcus infection]. ( Acar, M; Ağaçfidan, A; Aktürk, H; Beka, H; Hançerli Törün, S; Karagöz, N; Salman, N; Somer, A; Sütçü, M; Yekeler, E, 2016) |
| "Fluconazole is the standard treatment for oropharyngeal candidiasis, which is the third most common opportunistic infection in human immunodeficiency virus (HIV)/AIDS patients in Indonesia." | 3.81 | Overexpression and mutation as a genetic mechanism of fluconazole resistance in Candida albicans isolated from human immunodeficiency virus patients in Indonesia. ( Lestari, DC; Rosana, Y; Yasmon, A, 2015) |
| "A 52-year-old man with well-controlled HIV infection taking ritonavir and increasing doses of inhaled fluticasone for chronic bronchitis developed thrush." | 3.78 | Role of fluconazole in a case of rapid onset ritonavir and inhaled fluticasone-associated secondary adrenal insufficiency. ( Maguire, JD; St Clair, K, 2012) |
| " We sought to define the cost-effectiveness of serum cryptococcal antigen (CRAG) screening to identify persons with subclinical cryptococcosis and the efficacy of preemptive fluconazole therapy." | 3.76 | Cost-effectiveness of serum cryptococcal antigen screening to prevent deaths among HIV-infected persons with a CD4+ cell count < or = 100 cells/microL who start HIV therapy in resource-limited settings. ( Bohjanen, PR; Boulware, DR; Castelnuovo, B; Cook, BA; Elbireer, AM; Kambugu, A; Kamya, MR; Manabe, YC; Meya, DB, 2010) |
| "We report on the correlation of the outcomes for two cohorts of patients who had been treated for candidemia (126 episodes) or oropharyngeal candidiasis (110 episodes) with various doses of fluconazole and the MIC of fluconazole obtained by using the EUCAST standard for fermentative yeasts." | 3.74 | Correlation of the MIC and dose/MIC ratio of fluconazole to the therapeutic response of patients with mucosal candidiasis and candidemia. ( Almirante, B; Cuenca-Estrella, M; Donnelly, JP; Laguna, F; Mouton, JW; Pahissa, A; Rodríguez-Pardo, D; Rodríguez-Tudela, JL, 2007) |
| "This study aimed to test the MICs (minimal inhibitory concentrations) to fluconazole of Candida species isolated from mouthwash specimens of 54 HIV positive patients with oral candidiasis." | 3.71 | Clinical and mycological responses to fluconazole and fluconazole MIC in oropharyngeal candidiasis in HIV-infected patients. ( Bussaratid, V; Howe, P; Phonrat, B; Pitisuttithum, P; Simpson, A; Tansupasawasdikul, S; White, NJ, 2002) |
| " Other topics included an outline of the World Health Organization's (WHO) stepped-care strategy for pain management, a discussion on the benefits of fluconazole prophylaxis in treating opportunistic infections, and the need to confirm self-reported HIV infection to avoid the problem of some people attempting to gain a secondary benefit by claiming to be HIV-positive." | 3.69 | First women's HIV conference hears go-for-broke antiretroviral strategy. ( Mascolini, M, 1995) |
| "We have reviewed the efficacy of the use of fluconazole in patients with definitely proven Candida esophagitis (CE) associated with human immunodeficiency virus (HIV) infection, using a single 400 mg oral dose of fluconazole and evaluating the patient three days afterwards." | 3.68 | [Candida esophagitis treated with a single dose of fluconazole in patients with HIV: presentation of 11 cases]. ( Carrasco, R; Martínez, A; Medina, E; Navarro, V; Nieto, A; Roig, P; Salavert, M, 1990) |
| " With the exception of a higher incidence of gastrointestinal side effects in the 2000mg cohort, both induction doses of FCZ were safe and well tolerated." | 3.30 | Higher Dose Oral Fluconazole for the Treatment of AIDS-related Cryptococcal Meningitis (HIFLAC)-report of A5225, a multicentre, phase I/II, two-stage, dose-finding, safety, tolerability and efficacy randomised, amphotericin B-controlled trial of the AIDS ( Aberg, JA; Badal-Faesen, S; Bukuru, A; Clifford, DB; Hogg, E; Komarow, L; Lagat, D; Lalloo, UG; Langat, D; Larsen, RA; Mave, V; McKhann, A; Pillay, S; Samaneka, W; Supparatpinyo, K; Ticona, E, 2023) |
| "Cryptococcal meningitis is a leading cause of human immunodeficiency virus (HIV)-related death in sub-Saharan Africa." | 3.11 | Single-Dose Liposomal Amphotericin B Treatment for Cryptococcal Meningitis. ( Boulware, DR; Boyer-Chammard, T; Chawinga, C; Chen, T; Comins, K; Harrison, TS; Hlupeni, A; Hope, W; Hosseinipour, MC; Jaffar, S; Jarvis, JN; Jjunju, S; Kagimu, E; Kanyama, C; Kasibante, J; Lalloo, DG; Lawrence, DS; Leeme, T; Lortholary, O; Loyse, A; Meintjes, G; Meya, DB; Molloy, SF; Mosepele, M; Moyo, M; Mpoza, E; Mutata, C; Muzoora, C; Mwandumba, HC; Mzinganjira, H; Ndhlovu, CE; Nuwagira, E; Rhein, J; Rutakingirwa, MK; Schutz, C; Siamisang, K; Singh, A; Ssebambulidde, K; Tugume, L; van Widenfelt, E; Wang, D; Youssouf, N, 2022) |
| "Cryptococcal meningitis is a devastating brain infection cause by encapsulated yeasts of the Cryptococcus genus." | 2.82 | Treatment of Cryptococcal Meningitis: How Have We Got Here and Where are We Going? ( Day, JN; Flower, B; Ngan, NTT, 2022) |
| " All treatments and combinations were well tolerated, with no grade 3 or 4 adverse events observed during treatment." | 2.78 | Pharmacokinetics and short-term safety of etravirine in combination with fluconazole or voriconazole in HIV-negative volunteers. ( Aharchi, F; Hoetelmans, RM; Kakuda, TN; Nijs, S; Smedt, GD; Van Solingen-Ristea, R; Vyncke, V; Witek, J, 2013) |
| "High fluconazole dosage (800 mg/day) for the treatment of HIV-associated cryptococcal meningitis was associated with high serum and CSF fluconazole concentration." | 2.75 | Monitoring and impact of fluconazole serum and cerebrospinal fluid concentration in HIV-associated cryptococcal meningitis-infected patients. ( Andes, D; Anekthananon, T; Chetchotisakd, P; Filler, SG; Larsen, RA; Manosuthi, W; Nolen, TL; Pappas, PG; Sungkanuparph, S; Supparatpinyo, K; Wallace, D, 2010) |
| " Fluconazole at a dosage of 1200 mg per day is more fungicidal than at a dosage of 800 mg per day, but mortality rates remain unacceptably high." | 2.75 | Combination flucytosine and high-dose fluconazole compared with fluconazole monotherapy for the treatment of cryptococcal meningitis: a randomized trial in Malawi. ( Harrison, TS; Hosseinipour, MC; Jackson, A; Jaffar, S; Jarvis, JN; Kamwendo, D; Kanyemba, C; Kenala, J; Namarika, D; Nussbaum, JC; Phulusa, J; van der Horst, CM, 2010) |
| "BACKGROUND." | 2.75 | Early versus delayed initiation of antiretroviral therapy for concurrent HIV infection and cryptococcal meningitis in sub-saharan Africa. ( Gona, P; Hakim, JG; Kurangwa, M; Makadzange, AT; Ndhlovu, CE; Reid, M; Takarinda, K, 2010) |
| "7 mg/kg plus fluconazole 800 mg (the high-dosage combination) administered daily for 14 days, followed by fluconazole alone at the randomized dosage (400 or 800 mg per day) for 56 days." | 2.74 | A phase II randomized trial of amphotericin B alone or combined with fluconazole in the treatment of HIV-associated cryptococcal meningitis. ( Anekthananon, T; Chetchotisakd, P; Filler, SG; Johnson, P; Kendrick, AS; Larsen, RA; Manosuthi, W; Morris, MI; Nolen, TL; Pappas, PG; Sobel, JD; Sungkanuparph, S; Supparatpinyo, K; Zimmer, LO, 2009) |
| "The primary end points were bacterial vaginosis (BV), vaginal candidiasis, trichomoniasis vaginalis (hereafter, "trichomoniasis"), and colonization with Lactobacillus organisms." | 2.73 | Improvement of vaginal health for Kenyan women at risk for acquisition of human immunodeficiency virus type 1: results of a randomized trial. ( Baeten, JM; Chohan, V; Hassan, WM; Holmes, KK; Jaoko, W; Kiarie, J; Kurth, AE; Lavreys, L; Mandaliya, K; McClelland, RS; Ndinya-Achola, JO; Richardson, BA, 2008) |
| "Dapsone clearance was increased by rifabutin or rifabutin plus fluconazole (67% and 38%, respectively) (n = 12, P < ." | 2.71 | The effect of clarithromycin, fluconazole, and rifabutin on dapsone hydroxylamine formation in individuals with human immunodeficiency virus infection (AACTG 283). ( Greenspan, DL; Hooton, TM; Jacobson, M; Slattery, JT; Trapnell, CB; Unadkat, JD; Winter, HR, 2004) |
| " Pharmacokinetic parameters were determined on days 1 and 8." | 2.70 | The effect of fluconazole on ritonavir and saquinavir pharmacokinetics in HIV-1-infected individuals. ( Beijnen, JH; Burger, DM; Crommentuyn, KM; Hoetelmans, RM; Koks, CH; Koopmans, PP; Mathôt, RA; Meenhorst, PL; Mulder, JW, 2001) |
| "Blood and urine samples were obtained at regular intervals for 24 hours at the end of each 2-week dosing period to ascertain concentrations of fluconazole and rifabutin and the 25-desacetyl metabolite of rifabutin, LM565." | 2.68 | Increased plasma rifabutin levels with concomitant fluconazole therapy in HIV-infected patients. ( Lavelle, JP; Li, R; Narang, PK; Trapnell, CB, 1996) |
| "Fluconazole compliance was monitored electronically by using the Medication Event Monitoring Systems with 19 women receiving fluconazole at 50 mg thrice weekly for prophylaxis of recurrent mucocutaneous candidiasis." | 2.68 | Electronic compliance assessment of antifungal prophylaxis for human immunodeficiency virus-infected women. ( Bettencourt, FA; Dudley, MN; Fiore, TC; Flanigan, TP; Geletko, SM; Mayer, KH; Segarra, M, 1996) |
| "Fluconazole is a bis-triazole antifungal agent with a long serum half-life." | 2.67 | Fluconazole for oropharyngeal candidiasis in anti-HIV positive haemophiliacs. ( Hales, M; Kernoff, PB; Lee, CA; Lim, SG; O'Doherty, M; Winter, M, 1991) |
| "Fluconazole was well tolerated and prevented clinical relapse of oropharyngeal candidiasis in 71% of patients who completed three months of treatment (95% confidence interval [CI], 55-86) and 58% (95% CI, 41-75) who completed six months of treatment." | 2.67 | Fluconazole once a week as secondary prophylaxis against oropharyngeal candidiasis in HIV-infected patients. A double-blind placebo-controlled study. ( Harkness, JL; Hoy, JF; Jones, PD; Marriott, DJ; Speed, BR, 1993) |
| " In group 2, on 57 of 3316 days (2%), fluconazole in a higher dosage was administered for treatment." | 2.67 | Fluconazole prophylaxis of recurrent oral candidiasis in HIV-positive patients. ( Gentschew, G; Helm, EB; Just-Nübling, G; Meissner, K; Odewald, J; Staszewski, S; Stille, W, 1991) |
| "002) in the area under the serum concentration time curve (74%), the maximum serum concentration (84%), and the terminal half-life (128%) of zidovudine." | 2.67 | Effect of fluconazole on zidovudine pharmacokinetics in patients infected with human immunodeficiency virus. ( Cameron, DW; Gallicano, K; Pakuts, A; Sahai, J, 1994) |
| "Fluconazole was more effective than clotrimazole in eradicating Candida from the oral flora by the end of therapy (65% versus 48%) (p = 0." | 2.67 | Therapy for oropharyngeal candidiasis in HIV-infected patients: a randomized, prospective multicenter study of oral fluconazole versus clotrimazole troches. The Multicenter Study Group. ( Debruin, M; Greenspan, D; Pons, V, 1993) |
| "The major challenge in cryptococcal meningitis management has been the optimisation of induction phase treatment using the limited number of available medications, and major progress has recently been made." | 2.61 | Recent advances in managing HIV-associated cryptococcal meningitis. ( Alanio, A; Boyer-Chammard, T; Harrison, TS; Jarvis, JN; Lortholary, O; Temfack, E, 2019) |
| "Cryptococcal meningitis is a severe fungal infection that occurs primarily in the setting of advanced immunodeficiency and remains a major cause of HIV-related deaths worldwide." | 2.58 | Treatment for HIV-associated cryptococcal meningitis. ( Eshun-Wilson, I; Ford, N; Jarvis, JN; Li, T; Rouse, B; Shapiro, AE; Tenforde, MW, 2018) |
| "Two trials treated cryptococcal meningitis with amphotericin B and fluconazole; a third trial used fluconazole monotherapy; and the fourth trial did not specify the antifungal used." | 2.58 | Early versus delayed antiretroviral treatment in HIV-positive people with cryptococcal meningitis. ( Bicanic, T; Eshun-Wilson, I; Okwen, MP; Richardson, M, 2018) |
| "Symptoms of cryptococcal meningitis are non-specific: headache, fever, nausea, or altered mental state and behaviour." | 2.52 | [Cryptococcal meningitis]. ( Aliredjo, RP; de Jong, PY; de Sévaux, RG; Nooijen, S; van Spil, WE; Verhave, JC, 2015) |
| " The objective of this study was to compare the survival benefit between 5-FC (flucytosine) and fluconazole as second-line drugs given in combination with AmB." | 2.50 | Comparison of flucytosine and fluconazole combined with amphotericin B for the treatment of HIV-associated cryptococcal meningitis: a systematic review and meta-analysis. ( Lin, DF; Lu, X; Shen, C; Yao, ZW, 2014) |
| "In most people, untreated candidiasis persists for months or years unless associated risk factors are treated or eliminated." | 2.45 | Candidiasis (oropharyngeal). ( Pankhurst, CL, 2009) |
| "Amphotericin B based treatment is appropriate where possible." | 2.45 | Treatment of cryptococcal meningitis in resource limited settings. ( Dedicoat, MJ; Lalloo, DG; Sloan, DJ, 2009) |
| " The optimal dosing of AmB remains unclear." | 2.44 | Treatment of acute cryptococcal meningitis in HIV infected adults, with an emphasis on resource-limited settings. ( Dedicoat, M; Dlamini, S; Paul, N; Sloan, D, 2008) |
| " This formulation has a higher bioavailability and leads to higher local concentrations in the oral cavity which are advantages over the solid capsule formulation." | 2.41 | Itraconazole solution: summary of pharmacokinetic features and review of activity in the treatment of fluconazole-resistant oral candidosis in HIV-infected persons. ( Beijnen, JH; Bult, A; Koks, CH; Meenhorst, PL, 2002) |
| " The topical agents are available in assorted dosage forms with varying degrees of efficacy and patient acceptability." | 2.39 | Treatment of oropharyngeal candidiasis in HIV-positive patients. ( Greenspan, D, 1994) |
| "Fluconazole is a triazole antifungal agent which is now an established part of therapy in patients with immune deficiencies." | 2.39 | Fluconazole. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients. ( Barradell, LB; Goa, KL, 1995) |
| "Treatment with fluconazole led to mycologic cure and symptom improvement, although he subsequently underwent above-the-knee amputation due to continued joint instability." | 2.38 | Candida prosthetic arthritis: report of a case treated with fluconazole and review of the literature. ( Thomas, CY; Tunkel, AR; Wispelwey, B, 1993) |
| "Fluconazole is a new triazole antifungal agent with good activity against Candida and cryptococcal meningitis." | 2.38 | Fluconazole: a new option in the treatment of Candida mucositis and esophageal candidiasis. ( Garber, GE, 1992) |
| " Laboratory adverse events (grade 3 or 4), such as severe anemia, were less frequent with VCZ + 5FC use than with AmB-D combined with 5FC or Flu use." | 1.72 | Comparison of amphotericin B deoxycholate in combination with either flucytosine or fluconazole, and voriconazole plus flucytosine for the treatment of HIV-associated cryptococcal meningitis: a prospective multicenter study in China. ( Chen, Y; Harypursat, V; Lan, K; Lu, Y; Wu, Y; Xu, X; Yang, T; Yu, J; Zeng, Q; Zhang, W; Zhao, T; Zhou, G, 2022) |
| "Flucytosine-based treatment can be delivered in routine care in a middle-income country with a substantial survival benefit." | 1.72 | Outcomes of flucytosine-containing combination treatment for cryptococcal meningitis in a South African national access programme: a cross-sectional observational study. ( Black, J; Boretti, L; Garcia, A; Govender, NP; Greene, GS; Harrison, TS; Madua, M; Mashau, RC; Meintjes, G; Meiring, ST; Menezes, C; Nel, J; Quan, VC; Reddy, DL; Shroufi, A; Stacey, S; Trivino-Duran, L; Venter, M, 2022) |
| "He had multiple prior episodes of cryptococcal meningitis with complications necessitating ventriculoperitoneal shunt placement and was on suppressive fluconazole when he developed worsening brain manifestations." | 1.56 | Case Report: A Case of Severe Cryptococcal Immune Reconstitution Inflammatory Syndrome Presenting with Brain and Intradural Abscesses in an HIV Patient. ( Jeng, A; Kalinoski, T; Malenfant, J; Yim, C, 2020) |
| "Postmortem cryptococcal meningitis and pulmonary cryptococcosis were identified at MIA in all 4 CrAg-positive participants, 3 of whom had negative cerebrospinal fluid CrAg tests from lumbar punctures (LPs) at the time of CrAg screening." | 1.56 | Cryptococcal-related Mortality Despite Fluconazole Preemptive Treatment in a Cryptococcal Antigen Screen-and-Treat Program. ( Govender, NP; Harrison, TS; Ismail, NA; Jarvis, JN; Karat, AS; Mazanderani, AH; Nel, C; Omar, T; Tiemessen, CT; Wake, RM, 2020) |
| "The present study showed that mixed infections exist and could be of particular importance for care outcomes." | 1.51 | Cryptococcus genetic diversity and mixed infections in Ivorian HIV patients: A follow up study. ( Bellet, V; Bertout, S; Chabrol, A; Delaporte, E; Doumbia, A; Drakulovski, P; Kakou, A; Kassi, FK; Krasteva, D; Landman, R; Menan, HEI; Reynes, J; Roger, F, 2019) |
| "Amphotericin B was used in 13 patients." | 1.51 | [Forty cases of neuromeningeal cryptococcosis diagnosed at the Mycology-Parasitology Department of the Ibn Sina hospital in Rabat, over a 21-year period]. ( Aoufi, S; Bandadi, FZ; Lyagoubi, M; Moustachi, A; Raiss, C, 2019) |
| "Most had confirmed cryptococcal meningitis, and 54% (14/26) of the symptomatic CrAg+ persons were dead or lost at 6 months." | 1.48 | A Prospective Evaluation of a Multisite Cryptococcal Screening and Treatment Program in HIV Clinics in Uganda. ( Boulware, DR; Huppler Hullsiek, K; Lofgren, S; Meya, DB; Nalintya, E; Rajasingham, R, 2018) |
| "Stroke is an increasing cause of morbidity and mortality amongst HIV infected persons." | 1.48 | Ischemic stroke as a complication of cryptococcal meningitis and immune reconstitution inflammatory syndrome: a case report. ( Benjamin, LA; Ellis, JP; Harrison, TS; Heyderman, RS; Joekes, EC; Kalata, N; Kampondeni, S; Lalloo, DG, 2018) |
| "Fluconazole 1200mg was prescribed to 29 (63%) patients." | 1.46 | [Fluconazole 1200mg or 800mg for cryptococcal meningitis treatment in Ivory Coast]. ( Doumbia, A; Eholié, SP; Ehui, E; Ello, NF; Kassi, FK; Kassi, NA; Keita, M; Kouakou, GA; Mossou, C; Tanon, A, 2017) |
| " Of 4 children requiring prolonged amphotericin B and fluconazole at a dosage above 12 mg/kg/d, 3 presented with meningitis and 1 with fever." | 1.42 | Complicated and protracted cryptococcal disease in HIV-infected children. ( Cotton, MF; Hassan, H; Rabie, H, 2015) |
| "Fluconazole is a widely used antifungal agent used to treat Candida spp." | 1.42 | Influence of sustained low-efficiency diafiltration (SLED-f) on interstitial fluid concentrations of fluconazole in a critically ill patient: Use of microdialysis. ( Lipman, J; Peake, SL; Roberts, JA; Roberts, MS; Sinnollareddy, MG, 2015) |
| "Our case challenges the concept that immune reconstitution inflammatory syndrome and microbiological relapse are dichotomous entities." | 1.42 | Cryptococcal meningoencephalitis relapse after an eight-year delay: an interplay of infection and immune reconstitution. ( Arastéh, K; Blechschmidt, C; Boulware, DR; Branding, G; Katchanov, J; Meintjes, G; Nielsen, K; Stocker, H; Tintelnot, K, 2015) |
| "Cryptococcal meningitis is a mycosis encountered especially in patients with Acquired Immunodeficiency Syndrome and is fatal in the absence of treatment." | 1.42 | Cryptoccocal meningitis in Yaoundé (Cameroon) HIV infected patients: Diagnosis, frequency and Cryptococcus neoformans isolates susceptibility study to fluconazole. ( Bertout, S; Boyom, FF; Delaporte, E; Dongtsa, J; Fomena, S; Kammalac Ngouana, T; Kouanfack, C; Mallié, M; Tonfack, C, 2015) |
| "Flucytosine exposure was associated with a lower overall mortality rate (HR, 0." | 1.39 | Approaches to antifungal therapies and their effectiveness among patients with cryptococcosis. ( Bratton, EW; Chastain, CA; El Husseini, N; Juliano, JJ; Lee, MS; Perfect, JR; Poole, C; Stürmer, T; Weber, DJ, 2013) |
| " Fluconazole monotherapy is frequently recommended in national guidelines but is a fungistatic drug compromised by uncertainty over optimal dosing and a paucity of clinical end-point outcome data." | 1.39 | A prospective longitudinal study of the clinical outcomes from cryptococcal meningitis following treatment induction with 800 mg oral fluconazole in Blantyre, Malawi. ( Allain, T; Chikafa, J; Denis, B; Feasey, NA; Goodson, P; Harrison, T; Heyderman, RS; Lalloo, DG; Mukaka, M; Rothe, C; Sloan, DJ; van Oosterhout, JJ, 2013) |
| "Coccidioidomycosis is caused by the dimorphic fungus Coccidioides immitis, which is endemic in southwestern United States." | 1.38 | Coccidioidomycosis of cervical lymph nodes in an HIV-infected patient with immunologic reconstitution on potent HAART: a rare observation in a nonendemic area. ( D'Avino, A; Di Giambenedetto, S; Fabbiani, M; Farina, S, 2012) |
| "In many resource-limited settings, cryptococcal meningitis (CM) contributes up to 20% of all deaths with further complications due to Immune Reconstitution Inflammatory Syndrome (IRIS)." | 1.38 | Challenges in diagnosis and management of Cryptococcal immune reconstitution inflammatory syndrome (IRIS) in resource limited settings. ( Bohjanen, P; Lukande, R; Mayanja-Kizza, H; Meya, BD; Musubire, AK; R Boulware, RD; Wiesner, LD, 2012) |
| "Therefore cryptococcal lymphadenitis should be considered in the differential diagnosis of children presenting with lymphadenopathy and a positive serum CRAG." | 1.37 | A Case of Cryptococcal Lymphadenitis in an HIV-Infected Child. ( Kityo, C; Kizito, H; Mugyenyi, P; Musiime, V; Natukunda, E; Ssali, F, 2011) |
| "Cryptococcal meningitis is the commonest cause of adult meningitis in Southern Africa." | 1.36 | Symptomatic relapse of HIV-associated cryptococcal meningitis in South Africa: the role of inadequate secondary prophylaxis. ( Harrison, TS; Jarvis, JN; Meintjes, G; Rebe, K; Williams, Z, 2010) |
| "Oral candidiasis is the most prevalent complication in HIV-infected and AIDS patients." | 1.36 | In vitro activity of voriconazole against Mexican oral yeast isolates. ( Aguirre, JM; Carrillo-Muñoz, AJ; Eraso, E; Gaitán-Cepeda, LA; Quindós, G; Sánchez Vargas, LO, 2010) |
| "Micafungin has excellent antifungal effects in vitro against C." | 1.35 | Antifungal susceptibility testing of micafungin against Candida glabrata isolates. ( Fothergill, A; Kirkpatrick, WR; Oliveira, ER; Patterson, TF; Redding, SW, 2008) |
| " We compared patients who received 50 mg of caspofungin per day in a double-blind trial that used fluconazole as the comparator with patients who received the corresponding dosage in 2 similar earlier studies that used amphotericin as the comparator." | 1.35 | Double-blind active-control trials: beware the comparator you keep. ( Dinubile, MJ, 2008) |
| "To assess an optimal design that is sufficient to gain precise estimates of the pharmacokinetic (PK) parameters for fluconazole in people with HIV infection." | 1.35 | Development of a sufficient design for estimation of fluconazole pharmacokinetics in people with HIV infection. ( Duffull, SB; Kirkpatrick, CM; McLachlan, AJ; Roos, JF; Tett, SE, 2008) |
| "Fluconazole was used in 48% of the treatment episodes, amphotericin B in 46%, itraconazole in 4." | 1.34 | Drug-drug interactions with systemic antifungals in clinical practice. ( Abouelfath, A; Depont, F; Dupon, M; Dutronc, H; Galpérine, T; Giauque, E; Hébert, G; Moore, N; Ragnaud, JM; Valentino, R; Vargas, F, 2007) |
| "Treatment with Fluconazole for a period of four weeks successfully cured the infection." | 1.34 | Exacerbated inflammatory reaction to Trichophyton rubrum infection on an HIV-positive patient successfully treated with fluconazole. ( de Oliveira Teixeira, F; Mendoza, L; Vilela, L; Vilela, R, 2007) |
| " The objectives were to compare NVP levels, adverse events, and 36-week efficacy of NVP-based ART between patients who did not receive FLU (group A) and those who received FLU 200 mg/day or 400 mg/day (group B)." | 1.34 | Plasma nevirapine levels, adverse events and efficacy of antiretroviral therapy among HIV-infected patients concurrently receiving nevirapine-based antiretroviral therapy and fluconazole. ( Athichathanabadi, C; Manosuthi, W; Phoorisri, T; Sungkanuparph, S; Uttayamakul, S, 2007) |
| "Fluconazole resistance was found in five isolates, four exhibited dose-dependent susceptibility and the remainder were fully susceptible to this agent." | 1.33 | Molecular epidemiology of long-term colonization of Candida albicans strains from HIV-infected patients. ( Chen, KW; Cheng, HH; Chiou, CS; Hung, CC; Lauderdale, TL; Li, SY; Lo, HJ; Wang, TH; Yang, YL, 2006) |
| "Cryptococcosis is not rare in HIV-negative patients." | 1.33 | Cryptococcosis in human immunodeficiency virus-negative patients. ( Kiertiburanakul, S; Pracharktam, R; Sungkanuparph, S; Wirojtananugoon, S, 2006) |
| "To compare the adverse events after initiation of NVP-based ART among HIV-infected patients who did not receive fluconazole (group A), received fluconazole 400 mg/week (group B), and received fluconazole 200 mg/day (group C)." | 1.33 | Safety and tolerability of nevirapine-based antiretroviral therapy in HIV-infected patients receiving fluconazole for cryptococcal prophylaxis: a retrospective cohort study. ( Chaovavanich, A; Chumpathat, N; Manosuthi, W; Sungkanuparph, S, 2005) |
| "Fluconazole is a triazole antifungal used to treat mycotic infections." | 1.33 | Prenatal exposure to fluconazole: an identifiable dysmorphic phenotype. ( Lopez-Rangel, E; Van Allen, MI, 2005) |
| "Candidiasis is a significant cause of morbidity and mortality in immunosuppressed individuals." | 1.32 | Candida albicans switch phenotypes display differential levels of fitness. ( Holke, A; Joly, S; Morris, R; Sifri, T; Srikantha, R; Vargas, K, 2004) |
| "Fluconazole MICs were determined by using NCCLS methods." | 1.31 | Replacement of Candida albicans with C. dubliniensis in human immunodeficiency virus-infected patients with oropharyngeal candidiasis treated with fluconazole. ( Bachmann, SP; Coco, BJ; Kirkpatrick, WR; López-Ribot, JL; Martinez, M; Patterson, TF, 2002) |
| "Oral candidiasis is one of the earliest and most frequent complications of a failing immune system in HIV-infected individuals." | 1.30 | Stable azole drug resistance associated with a substrain of Candida albicans from an HIV-infected patient. ( Pfaller, MA; Redding, SW; Rinaldi, MG; Smith, J; White, TC, 1997) |
| "A cryptococcus neoformans septicemia with meningoencephalitis was diagnosed." | 1.30 | Cryptococcosis, epileptic seizures and encephalopathy in a HIV-infected patient. ( Elzi, M; Reusser, P; Tolnay, M, 1997) |
| "Fluconazole has been prescribed in 7 patients as a permanent suppressive therapy and should be continued indefinitely." | 1.30 | [Pulmonary cryptococcosis during HIV infection. 15 cases]. ( Balloul, E; Cahite, I; Caubarrère, I; Couderc, LJ; Molina, JM; Saimot, AG; Wolff, M, 1997) |
| "Treatment with fluconazole (100 mg/day) was successful in 86% of the cases." | 1.29 | Correlation between in vitro resistance to fluconazole and clinical outcome of oropharyngeal candidiasis in HIV-infected patients. ( Baquero, F; Fortún, J; Giner, C; Guerrero, A; Navas, E; Pereira, E; Polanco, AM; Quereda, C; Sánchez-Sousa, A, 1996) |
| " Plasma concentration-time data (between 1 and 17 observations per dose) were collected from individuals as part of a pharmacokinetic investigation (13 subjects) or during routine fluconazole therapy (100 subjects) for the treatment or prophylaxis of fungal infection." | 1.29 | Pharmacokinetics of fluconazole in people with HIV infection: a population analysis. ( McLachlan, AJ; Tett, SE, 1996) |
| " Pharmacokinetic parameters indicated linearity in all subjects; the area under the plasma concentration-time curve and the maximum concentration increased in proportion to the dose." | 1.29 | Pharmacokinetics and bioavailability of fluconazole in two groups of males with human immunodeficiency virus (HIV) infection compared with those in a group of males without HIV infection. ( Moore, S; Ray, J; Tett, S, 1995) |
| "Product-limit survival and incidence of AIDS-defining events were calculated as a function of baseline CD4 count." | 1.29 | Logarithmic relationship of the CD4 count to survival in patients with human immunodeficiency virus infection. ( Cal, SX; Haslund, I; Jockusch, JD; Loss, SD; Nightingale, SD; Peterson, DM, 1993) |
| "esophagitis is common in HIV-infected patients." | 1.28 | Clinical, endoscopic, immunologic, and therapeutic aspects of oropharyngeal and esophageal candidiasis in HIV-infected patients: a survey of 114 cases. ( Aguado, AG; Khamashta, MA; López-Dupla, M; Mora Sanz, P; Pintado García, V; Uriol, PL; Valencia Ortega, E, 1992) |
| "Treatment with fluconazole seems to be an effective alternative in treatment of CNM." | 1.28 | [Fluconazole treatment of cryptococcal meningitis associated with HIV infection. Presentation of 4 cases]. ( Bernacer, B; Carrasco, R; Navarro, V; Nieto, A; Rodríguez, M; Roig, P; Salavert, M, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 80 (26.76) | 18.2507 |
| 2000's | 79 (26.42) | 29.6817 |
| 2010's | 100 (33.44) | 24.3611 |
| 2020's | 40 (13.38) | 2.80 |
| Authors | Studies |
|---|---|
| Müller, FM | 2 |
| Staudigel, A | 1 |
| Salvenmoser, S | 1 |
| Tredup, A | 1 |
| Miltenberger, R | 1 |
| Herrmann, JV | 1 |
| Liu, J | 1 |
| Li, M | 1 |
| Liang, JY | 1 |
| Xu, XF | 1 |
| Zeng, WG | 1 |
| Wang, YJ | 1 |
| Jiang, Y | 1 |
| Peng, FH | 1 |
| Yang, C | 1 |
| Bian, Z | 1 |
| Blechert, O | 1 |
| Deng, F | 1 |
| Chen, H | 1 |
| Li, Y | 1 |
| Yang, Y | 1 |
| Chen, M | 2 |
| Zhan, P | 1 |
| Tan, L | 1 |
| Shi, H | 1 |
| Wang, Z | 1 |
| Yao, Z | 1 |
| Sun, Y | 1 |
| Rajasingham, R | 8 |
| Nalintya, E | 4 |
| Israelski, DM | 1 |
| Meya, DB | 12 |
| Larson, BA | 1 |
| Boulware, DR | 17 |
| Jarvis, JN | 11 |
| Lawrence, DS | 4 |
| Kagimu, E | 1 |
| Kasibante, J | 1 |
| Mpoza, E | 2 |
| Rutakingirwa, MK | 1 |
| Ssebambulidde, K | 3 |
| Tugume, L | 4 |
| Rhein, J | 4 |
| Mwandumba, HC | 2 |
| Moyo, M | 1 |
| Mzinganjira, H | 1 |
| Kanyama, C | 3 |
| Hosseinipour, MC | 3 |
| Chawinga, C | 2 |
| Meintjes, G | 8 |
| Schutz, C | 3 |
| Comins, K | 1 |
| Singh, A | 1 |
| Muzoora, C | 4 |
| Jjunju, S | 1 |
| Nuwagira, E | 3 |
| Mosepele, M | 2 |
| Leeme, T | 1 |
| Siamisang, K | 1 |
| Ndhlovu, CE | 2 |
| Hlupeni, A | 1 |
| Mutata, C | 1 |
| van Widenfelt, E | 1 |
| Chen, T | 1 |
| Wang, D | 1 |
| Hope, W | 1 |
| Boyer-Chammard, T | 3 |
| Loyse, A | 6 |
| Molloy, SF | 4 |
| Youssouf, N | 1 |
| Lortholary, O | 10 |
| Lalloo, DG | 5 |
| Jaffar, S | 3 |
| Harrison, TS | 15 |
| Nyirjesy, P | 1 |
| Brookhart, C | 1 |
| Lazenby, G | 1 |
| Schwebke, J | 1 |
| Sobel, JD | 4 |
| Lomeli-Martinez, SM | 1 |
| González-Hernández, LA | 1 |
| Villanueva, JFA | 1 |
| Valentín-Goméz, E | 1 |
| Ratkovich-González, S | 1 |
| Alvarez-Zavala, M | 1 |
| Sánchez-Reyes, K | 1 |
| Cabrera-Silva, RI | 1 |
| Varela-Hernández, JJ | 1 |
| Sousa, BR | 1 |
| Freitas, JF | 1 |
| Valeriano, CA | 1 |
| Neto, LN | 1 |
| Neves, RP | 1 |
| Gambarra, FF | 1 |
| Gomes, TM | 1 |
| da Silva Acioly, JC | 1 |
| Lima-Neto, RG | 1 |
| Mashau, RC | 1 |
| Meiring, ST | 1 |
| Quan, VC | 1 |
| Nel, J | 1 |
| Greene, GS | 1 |
| Garcia, A | 1 |
| Menezes, C | 1 |
| Reddy, DL | 1 |
| Venter, M | 1 |
| Stacey, S | 1 |
| Madua, M | 1 |
| Boretti, L | 1 |
| Shroufi, A | 2 |
| Trivino-Duran, L | 1 |
| Black, J | 1 |
| Govender, NP | 3 |
| Naicker, SD | 1 |
| Firacative, C | 1 |
| van Schalkwyk, E | 1 |
| Maphanga, TG | 1 |
| Monroy-Nieto, J | 1 |
| Bowers, JR | 1 |
| Engelthaler, DM | 1 |
| Meyer, W | 1 |
| Zhao, T | 1 |
| Xu, X | 1 |
| Wu, Y | 2 |
| Zhang, W | 1 |
| Zeng, Q | 1 |
| Lu, Y | 1 |
| Yang, T | 1 |
| Zhou, G | 1 |
| Yu, J | 1 |
| Lan, K | 1 |
| Harypursat, V | 1 |
| Chen, Y | 1 |
| Wang, F | 1 |
| Namuju, OC | 1 |
| Pastick, KA | 3 |
| Abdusalaamu, K | 1 |
| Mishra, U | 1 |
| Collins, L | 1 |
| Lukande, R | 2 |
| Nicol, MR | 2 |
| Zhao, HZ | 1 |
| Cheng, JH | 1 |
| Zhou, LH | 1 |
| Luo, Y | 1 |
| Zhu, RS | 1 |
| Jiang, YK | 1 |
| Wang, X | 1 |
| Zhu, LP | 1 |
| Ngan, NTT | 1 |
| Flower, B | 1 |
| Day, JN | 1 |
| Shapiro, AE | 2 |
| Tenforde, MW | 3 |
| Chiller, TM | 1 |
| Ford, N | 4 |
| Ssali, A | 2 |
| Moshashane, N | 1 |
| Nabaggala, G | 1 |
| Maphane, L | 1 |
| Seeley, J | 2 |
| Samukawa, S | 3 |
| Yoshimi, R | 3 |
| Kojitani, N | 3 |
| Uzawa, Y | 3 |
| Takase-Minegishi, K | 3 |
| Kirino, Y | 3 |
| Soejima, Y | 3 |
| Kato, H | 3 |
| Nakajima, H | 3 |
| Torres, I | 2 |
| Gallo, JE | 2 |
| Gómez, OM | 2 |
| Rúa-Giraldo, Á | 2 |
| McEwen, JG | 2 |
| García, AM | 2 |
| Thanyasrisung, P | 1 |
| Satitviboon, W | 1 |
| Howattanapanich, S | 1 |
| Matangkasombut, O | 1 |
| Lalloo, UG | 1 |
| Komarow, L | 1 |
| Aberg, JA | 1 |
| Clifford, DB | 1 |
| Hogg, E | 1 |
| McKhann, A | 1 |
| Bukuru, A | 1 |
| Lagat, D | 1 |
| Pillay, S | 1 |
| Mave, V | 1 |
| Supparatpinyo, K | 5 |
| Samaneka, W | 1 |
| Langat, D | 1 |
| Ticona, E | 1 |
| Badal-Faesen, S | 1 |
| Larsen, RA | 5 |
| Erfaninejad, M | 1 |
| Zarei Mahmoudabadi, A | 1 |
| Maraghi, E | 1 |
| Hashemzadeh, M | 1 |
| Fatahinia, M | 1 |
| Bive, BZ | 1 |
| Sacheli, R | 1 |
| Mudogo, CN | 1 |
| Zakayi, PK | 1 |
| Bontems, S | 1 |
| Lelo, GM | 1 |
| Hayette, MP | 1 |
| Ehemann, K | 1 |
| Contreras, A | 1 |
| Celis-Ramírez, AM | 1 |
| Alhadab, AA | 2 |
| Musubire, A | 1 |
| Williams, DA | 2 |
| Abassi, M | 2 |
| Brundage, RC | 1 |
| Temfack, E | 5 |
| Lawrence, D | 1 |
| Delliere, S | 1 |
| Lanternier, F | 1 |
| Alanio, A | 2 |
| Morare, NMT | 1 |
| Rose, DM | 1 |
| Appels, O | 1 |
| Stephens, N | 1 |
| Evans, EE | 2 |
| Ndyetukira, JF | 1 |
| Skipper, C | 1 |
| Bandadi, FZ | 1 |
| Raiss, C | 1 |
| Moustachi, A | 1 |
| Lyagoubi, M | 1 |
| Aoufi, S | 1 |
| Kassi, FK | 3 |
| Drakulovski, P | 2 |
| Bellet, V | 2 |
| Roger, F | 2 |
| Chabrol, A | 1 |
| Krasteva, D | 2 |
| Doumbia, A | 3 |
| Landman, R | 1 |
| Kakou, A | 1 |
| Reynes, J | 3 |
| Delaporte, E | 3 |
| Menan, HEI | 1 |
| Bertout, S | 4 |
| Monzani, V | 1 |
| Córdoba, S | 2 |
| Vivot, M | 1 |
| Arias, B | 1 |
| Vivot, W | 2 |
| Szusz, W | 2 |
| Castellaro, P | 1 |
| Appendino, A | 1 |
| Taverna, CG | 1 |
| Pullen, MF | 1 |
| Hullsiek, KH | 2 |
| Musubire, AK | 2 |
| Kiggundu, R | 1 |
| Akampurira, A | 2 |
| Nabeta, HW | 1 |
| Skipper, CP | 1 |
| Morawski, BM | 2 |
| Bangdiwala, AS | 1 |
| Gertz, AM | 1 |
| Wills, NK | 1 |
| Guthrie, BL | 1 |
| Farquhar, C | 1 |
| Lakoh, S | 1 |
| Rickman, H | 1 |
| Sesay, M | 1 |
| Kenneh, S | 1 |
| Burke, R | 1 |
| Baldeh, M | 1 |
| Jiba, DF | 1 |
| Tejan, YS | 1 |
| Boyle, S | 1 |
| Koroma, C | 1 |
| Deen, GF | 1 |
| Beynon, F | 1 |
| Kalinoski, T | 1 |
| Malenfant, J | 1 |
| Yim, C | 1 |
| Jeng, A | 1 |
| Murray, M | 1 |
| Hine, P | 1 |
| Hu, D | 1 |
| Zhang, Q | 1 |
| Jiang, W | 1 |
| Arastehfar, A | 1 |
| Ilkit, M | 1 |
| Fang, W | 1 |
| Li, H | 1 |
| Chen, X | 1 |
| Zhang, L | 2 |
| Li, X | 2 |
| Pan, W | 2 |
| Liao, W | 2 |
| Ramírez-Amador, V | 1 |
| Patton, LL | 1 |
| Naglik, JR | 1 |
| Nittayananta, W | 1 |
| Quincho-Lopez, A | 1 |
| Montenegro-Idrogo, J | 1 |
| Verona-Rubio, RO | 1 |
| Vidal, JE | 1 |
| de Albuquerque Moraes, C | 1 |
| de Siqueira, REB | 1 |
| Miranda, NFB | 1 |
| Marcusso, R | 1 |
| de Oliveira, ACP | 1 |
| Tamai, IA | 1 |
| Pakbin, B | 1 |
| Fasaei, BN | 1 |
| Drain, PK | 1 |
| Galagan, SR | 1 |
| Govere, S | 1 |
| Krows, M | 1 |
| Thulare, H | 1 |
| Wallis, CL | 1 |
| Gosnell, BI | 1 |
| Moosa, MY | 1 |
| Celum, C | 1 |
| Bassett, IV | 1 |
| Bremer, M | 1 |
| Kadernani, YE | 1 |
| Wasserman, S | 1 |
| Wilkinson, RJ | 1 |
| Davis, AG | 1 |
| Schattner, A | 1 |
| Finn, T | 1 |
| Glick, Y | 1 |
| Concha-Velasco, F | 1 |
| González-Lagos, E | 1 |
| Seas, C | 1 |
| Bustamante, B | 1 |
| Sungkanuparph, S | 7 |
| Savetamornkul, C | 1 |
| Pattanapongpaiboon, W | 1 |
| Frola, C | 1 |
| Guelfand, L | 1 |
| Blugerman, G | 1 |
| Szyld, E | 1 |
| Kaufman, S | 1 |
| Cahn, P | 1 |
| Sued, O | 1 |
| Pérez, H | 1 |
| Ming, DK | 1 |
| Sony, P | 1 |
| Kalyani, M | 1 |
| Jeyakumari, D | 1 |
| Kannan, I | 2 |
| Sukumar, RG | 1 |
| Beyene, T | 1 |
| Zewde, AG | 1 |
| Balcha, A | 1 |
| Hirpo, B | 1 |
| Yitbarik, T | 1 |
| Gebissa, T | 1 |
| Pasquier, E | 1 |
| Kunda, J | 1 |
| De Beaudrap, P | 1 |
| Valérie, BA | 1 |
| Aboubakar, T | 1 |
| Kouakou, GA | 2 |
| Yavo, W | 1 |
| Menan, HIE | 1 |
| Lofgren, S | 1 |
| Huppler Hullsiek, K | 1 |
| Johnson, WJ | 1 |
| Blice, JP | 1 |
| Lee, KK | 1 |
| Brilhante, RSN | 1 |
| Guedes, GMM | 1 |
| Silva, MLQD | 1 |
| Castelo-Branco, DSCM | 1 |
| Cordeiro, RA | 1 |
| Sidrim, JJC | 1 |
| Rocha, MFG | 1 |
| Paul, S | 1 |
| Mohanram, K | 1 |
| Fay, VDS | 1 |
| Rodrigues, DMG | 1 |
| Gonçalves, SMB | 1 |
| Gregianini, TS | 1 |
| Bonamigo, RR | 1 |
| Khedri, S | 1 |
| Santos, ALS | 1 |
| Roudbary, M | 1 |
| Hadighi, R | 1 |
| Falahati, M | 1 |
| Farahyar, S | 1 |
| Khoshmirsafa, M | 1 |
| Kalantari, S | 1 |
| Bigna, JJ | 1 |
| Luma, HN | 1 |
| Spijker, R | 1 |
| Dromer, F | 4 |
| Harrison, T | 3 |
| Cohen, JF | 1 |
| Eshun-Wilson, I | 3 |
| Okwen, MP | 1 |
| Richardson, M | 1 |
| Bicanic, T | 3 |
| Rouse, B | 1 |
| Li, T | 1 |
| Goulart, LS | 1 |
| Souza, WWR | 1 |
| Vieira, CA | 1 |
| Lima, JS | 1 |
| Olinda, RA | 1 |
| Araújo, C | 1 |
| Bradley, J | 1 |
| Karunaharan, N | 1 |
| Mputu, M | 1 |
| Stone, N | 1 |
| Phulusa, J | 2 |
| Gaskell, K | 1 |
| Segula, D | 1 |
| Ming, D | 1 |
| Peirse, M | 1 |
| Chanda, D | 2 |
| Lakhi, S | 2 |
| Heyderman, RS | 3 |
| Ellis, JP | 1 |
| Kalata, N | 2 |
| Joekes, EC | 1 |
| Kampondeni, S | 1 |
| Benjamin, LA | 1 |
| Burry, J | 1 |
| Cohn, J | 1 |
| Chiller, T | 1 |
| Ribeiro, I | 1 |
| Koulla-Shiro, S | 1 |
| Mghamba, J | 1 |
| Ramadhani, A | 1 |
| Nyirenda, R | 1 |
| Aliyu, SH | 1 |
| Wilson, D | 1 |
| Le, T | 1 |
| Oladele, R | 1 |
| Lesikari, S | 1 |
| Mapoure, Y | 1 |
| Sini, V | 1 |
| Shimwela, M | 1 |
| Ngoma, J | 1 |
| Gondwe-Chunda, L | 1 |
| Perfect, C | 1 |
| Andrieux-Meyer, I | 1 |
| Chan, A | 1 |
| Hosseinipour, M | 1 |
| Van der Horst, C | 1 |
| Klausner, JD | 1 |
| Heyderman, R | 1 |
| Lalloo, D | 1 |
| Day, J | 2 |
| Rodrigues, M | 1 |
| Denning, D | 1 |
| Migone, C | 2 |
| Doherty, M | 1 |
| Stack, M | 1 |
| van Oosterhout, J | 1 |
| Mwaba, P | 1 |
| Kouanfack, C | 3 |
| Mfinanga, S | 1 |
| Govender, N | 3 |
| Kiragga, AN | 1 |
| Park, BJ | 2 |
| Mubiru, A | 1 |
| Kaplan, JE | 1 |
| Manabe, YC | 2 |
| Faini, D | 1 |
| Kalinjuma, AV | 1 |
| Katende, A | 1 |
| Mbwaji, G | 1 |
| Mnzava, D | 1 |
| Nyuri, A | 1 |
| Glass, TR | 1 |
| Furrer, H | 1 |
| Hatz, C | 1 |
| Letang, E | 1 |
| Garner, P | 1 |
| Castillo-Martínez, NA | 1 |
| Mouriño-Pérez, RR | 1 |
| Cornejo-Bravo, JM | 1 |
| Gaitán-Cepeda, LA | 3 |
| Sivaraj, V | 1 |
| Kulasegaram, R | 1 |
| Rickaby, W | 1 |
| Dwyer, E | 1 |
| Vechi, HT | 1 |
| Theodoro, RC | 1 |
| de Oliveira, AL | 1 |
| Gomes, RMODS | 1 |
| Soares, RDA | 1 |
| Freire, MG | 1 |
| Bay, MB | 1 |
| Khan, AT | 1 |
| Dhorajiya, P | 1 |
| Lung, E | 1 |
| Li, Z | 1 |
| Liu, Y | 1 |
| Chong, Y | 1 |
| Jie, Y | 1 |
| Zheng, X | 1 |
| Yan, Y | 1 |
| Lin, AY | 1 |
| Chun, V | 1 |
| Dhamija, A | 1 |
| Bordin-Wosk, T | 1 |
| Kadakia, A | 1 |
| Wake, RM | 1 |
| Omar, T | 1 |
| Nel, C | 1 |
| Mazanderani, AH | 1 |
| Karat, AS | 1 |
| Ismail, NA | 1 |
| Tiemessen, CT | 1 |
| Ngouana, TK | 1 |
| Toghueo, RMK | 1 |
| Kenfack, IF | 1 |
| Lachaud, L | 1 |
| Nana, AK | 1 |
| Tadjou, L | 1 |
| Boyom, FF | 2 |
| Bratton, EW | 1 |
| El Husseini, N | 1 |
| Chastain, CA | 1 |
| Lee, MS | 1 |
| Poole, C | 1 |
| Stürmer, T | 1 |
| Weber, DJ | 1 |
| Juliano, JJ | 1 |
| Perfect, JR | 3 |
| La Hoz, RM | 1 |
| Pappas, PG | 5 |
| Maurya, V | 1 |
| Srivastava, A | 1 |
| Mishra, J | 1 |
| Venkatesh, V | 1 |
| Rothe, C | 1 |
| Sloan, DJ | 2 |
| Goodson, P | 1 |
| Chikafa, J | 1 |
| Mukaka, M | 1 |
| Denis, B | 1 |
| van Oosterhout, JJ | 1 |
| Allain, T | 1 |
| Feasey, NA | 1 |
| Demiraslan, H | 1 |
| Alabay, S | 1 |
| Kilic, AU | 1 |
| Borlu, M | 1 |
| Doganay, M | 1 |
| Namukwaya, S | 1 |
| Bufumbo, L | 1 |
| G Lalloo, D | 1 |
| Kamali, A | 1 |
| Parkes-Ratanshi, R | 2 |
| Yao, ZW | 1 |
| Lu, X | 1 |
| Shen, C | 1 |
| Lin, DF | 1 |
| Rwegerera, GM | 1 |
| Chowdhury, W | 1 |
| Setime, MA | 1 |
| Vento, S | 1 |
| Meda, J | 1 |
| Kalluvya, S | 1 |
| Downs, JA | 2 |
| Chofle, AA | 1 |
| Seni, J | 1 |
| Kidenya, B | 1 |
| Fitzgerald, DW | 2 |
| Peck, RN | 2 |
| Jiang, L | 1 |
| Yong, X | 1 |
| Li, R | 2 |
| Peng, Y | 1 |
| Liu, W | 1 |
| Qin, Q | 1 |
| Liu, Z | 1 |
| Liang, H | 1 |
| Tao, R | 1 |
| Hassan, H | 1 |
| Cotton, MF | 1 |
| Rabie, H | 1 |
| Mosha, F | 1 |
| Ledwaba, J | 1 |
| Ndugulile, F | 1 |
| Ng'ang'a, Z | 1 |
| Nsubuga, P | 1 |
| Morris, L | 1 |
| Kasubi, M | 1 |
| Swai, A | 1 |
| Vercauteren, J | 1 |
| Vandamme, AM | 1 |
| Anil, S | 2 |
| Hashem, M | 1 |
| Vellappally, S | 1 |
| Patil, S | 1 |
| Bandara, HM | 1 |
| Samaranayake, LP | 3 |
| Yang, JJ | 1 |
| Huang, CH | 1 |
| Liu, CE | 1 |
| Tang, HJ | 1 |
| Yang, CJ | 1 |
| Lee, YC | 1 |
| Lee, KY | 1 |
| Tsai, MS | 1 |
| Lin, SW | 1 |
| Chen, YH | 1 |
| Lu, PL | 1 |
| Hung, CC | 4 |
| Kammalac Ngouana, T | 1 |
| Dongtsa, J | 1 |
| Tonfack, C | 1 |
| Fomena, S | 1 |
| Mallié, M | 2 |
| Katchanov, J | 2 |
| Blechschmidt, C | 1 |
| Nielsen, K | 2 |
| Branding, G | 2 |
| Arastéh, K | 2 |
| Tintelnot, K | 1 |
| Stocker, H | 2 |
| Jefferys, L | 1 |
| Siebert, E | 1 |
| van Spil, WE | 1 |
| Nooijen, S | 1 |
| de Jong, PY | 1 |
| Aliredjo, RP | 1 |
| de Sévaux, RG | 1 |
| Verhave, JC | 1 |
| Sinnollareddy, MG | 1 |
| Roberts, MS | 1 |
| Lipman, J | 1 |
| Peake, SL | 1 |
| Roberts, JA | 1 |
| Rosana, Y | 1 |
| Yasmon, A | 1 |
| Lestari, DC | 1 |
| Smith, KD | 1 |
| Achan, B | 1 |
| McDonald, TR | 1 |
| Okagaki, LH | 1 |
| Rhein, JR | 1 |
| Kapoor, SW | 1 |
| Magambo, KA | 1 |
| Kalluvya, SE | 1 |
| Isla, MG | 1 |
| Altamirano, R | 1 |
| Davel, G | 1 |
| Yeung, VA | 1 |
| Azzam, R | 1 |
| Dendle, C | 1 |
| Graham, M | 1 |
| Woolley, IJ | 1 |
| Korman, TM | 1 |
| Minea, B | 1 |
| Nastasa, V | 1 |
| Kolecka, A | 1 |
| Mares, M | 2 |
| Marangoci, N | 1 |
| Rosca, I | 1 |
| Pinteala, M | 1 |
| Hancianu, M | 1 |
| Das, PP | 1 |
| Saikia, L | 1 |
| Nath, R | 1 |
| Phukan, SK | 1 |
| Krysan, DJ | 1 |
| Acar, M | 1 |
| Sütçü, M | 1 |
| Aktürk, H | 1 |
| Hançerli Törün, S | 1 |
| Karagöz, N | 1 |
| Beka, H | 1 |
| Yekeler, E | 1 |
| Ağaçfidan, A | 1 |
| Salman, N | 1 |
| Somer, A | 1 |
| Grossman, NT | 1 |
| Casadevall, A | 1 |
| Ello, NF | 1 |
| Kassi, NA | 1 |
| Keita, M | 1 |
| Mossou, C | 1 |
| Tanon, A | 1 |
| Ehui, E | 1 |
| Eholié, SP | 1 |
| Shokri, H | 1 |
| Sharifzadeh, A | 1 |
| Nadagir, SD | 1 |
| Chunchanur, SK | 1 |
| Halesh, LH | 1 |
| Yasmeen, K | 1 |
| Chandrasekhar, MR | 1 |
| Patil, BS | 1 |
| Umamaheswari, K | 1 |
| Menon, T | 1 |
| Roos, JF | 1 |
| Kirkpatrick, CM | 1 |
| Tett, SE | 2 |
| McLachlan, AJ | 2 |
| Duffull, SB | 1 |
| Dinubile, MJ | 1 |
| Pasqualotto, AC | 1 |
| Hamza, OJ | 1 |
| Matee, MI | 1 |
| Brüggemann, RJ | 1 |
| Moshi, MJ | 1 |
| Simon, EN | 1 |
| Mugusi, F | 1 |
| Mikx, FH | 1 |
| van der Lee, HA | 1 |
| Verweij, PE | 1 |
| van der Ven, AJ | 1 |
| Sloan, D | 1 |
| Dlamini, S | 1 |
| Paul, N | 1 |
| Dedicoat, M | 1 |
| Amengual, JE | 1 |
| Zhang, X | 1 |
| Ibrahim, S | 1 |
| Gardner, LB | 1 |
| Monpoux, F | 1 |
| Pitelet, G | 1 |
| Richelme, C | 1 |
| Boutté, P | 1 |
| Kingkaew, N | 1 |
| Sangtong, B | 1 |
| Amnuaiphon, W | 1 |
| Jongpaibulpatana, J | 1 |
| Mankatittham, W | 1 |
| Akksilp, S | 1 |
| Sirinak, C | 1 |
| Nateniyom, S | 1 |
| Burapat, C | 1 |
| Kittikraisak, W | 1 |
| Monkongdee, P | 1 |
| Varma, JK | 1 |
| Makombe, SD | 1 |
| Nkhata, A | 1 |
| Schouten, EJ | 1 |
| Kamoto, K | 1 |
| Harries, AD | 1 |
| Enwuru, CA | 1 |
| Ogunledun, A | 1 |
| Idika, N | 1 |
| Enwuru, NV | 1 |
| Ogbonna, F | 1 |
| Aniedobe, M | 1 |
| Adeiga, A | 1 |
| Sánchez Vargas, LO | 1 |
| Eraso, E | 1 |
| Carrillo-Muñoz, AJ | 1 |
| Aguirre, JM | 2 |
| Quindós, G | 2 |
| Chetchotisakd, P | 4 |
| Manosuthi, W | 7 |
| Morris, MI | 1 |
| Anekthananon, T | 4 |
| Nolen, TL | 4 |
| Zimmer, LO | 2 |
| Kendrick, AS | 2 |
| Johnson, P | 1 |
| Filler, SG | 6 |
| Pankhurst, CL | 2 |
| Dedicoat, MJ | 1 |
| Costa, CR | 1 |
| Jesuíno, RS | 1 |
| de Aquino Lemos, J | 1 |
| de Fátima Lisboa Fernandes, O | 1 |
| Hasimoto e Souza, LK | 1 |
| Passos, XS | 1 |
| do Rosário Rodrigues Silva, M | 1 |
| Wallace, D | 1 |
| Andes, D | 1 |
| Wakeham, K | 1 |
| Watson, V | 1 |
| Ggayi, AB | 1 |
| Khoo, S | 1 |
| Nussbaum, JC | 1 |
| Jackson, A | 1 |
| Namarika, D | 1 |
| Kenala, J | 1 |
| Kanyemba, C | 1 |
| Kamwendo, D | 1 |
| van der Horst, CM | 1 |
| Fleischhacker, M | 1 |
| Pasligh, J | 1 |
| Moran, G | 1 |
| Ruhnke, M | 6 |
| Makadzange, AT | 1 |
| Takarinda, K | 1 |
| Reid, M | 1 |
| Kurangwa, M | 1 |
| Gona, P | 1 |
| Hakim, JG | 1 |
| Yang, YL | 4 |
| Wang, AH | 1 |
| Tseng, FC | 2 |
| Leaw, SN | 1 |
| Tseng, YT | 1 |
| Su, CL | 1 |
| Chen, HT | 2 |
| Lauderdale, TL | 3 |
| Lo, HJ | 4 |
| Williams, Z | 1 |
| Rebe, K | 2 |
| Castelnuovo, B | 1 |
| Cook, BA | 1 |
| Elbireer, AM | 1 |
| Kambugu, A | 1 |
| Kamya, MR | 1 |
| Bohjanen, PR | 1 |
| Micol, R | 1 |
| Tajahmady, A | 1 |
| Balkan, S | 1 |
| Quillet, C | 1 |
| Dousset, JP | 1 |
| Chanroeun, H | 1 |
| Madec, Y | 1 |
| Fontanet, A | 1 |
| Yazdanpanah, Y | 1 |
| Natukunda, E | 1 |
| Musiime, V | 1 |
| Ssali, F | 1 |
| Kizito, H | 1 |
| Kityo, C | 1 |
| Mugyenyi, P | 1 |
| Aberg, J | 1 |
| Powderly, W | 1 |
| Shetty, S | 1 |
| Ahlquist, A | 1 |
| Greenbaum, A | 1 |
| Miller, JL | 1 |
| Motsi, A | 1 |
| McCarthy, K | 1 |
| Nweze, EI | 1 |
| Ogbonnaya, UL | 1 |
| Rossouw, I | 1 |
| Goedhals, D | 1 |
| van der Merwe, J | 1 |
| Stallenberg, V | 1 |
| Schulz, B | 1 |
| Weber, K | 1 |
| Schmidt, A | 1 |
| Borg-von Zepelin, M | 1 |
| Lessells, RJ | 1 |
| Mutevedzi, PC | 1 |
| Heller, T | 1 |
| Newell, ML | 1 |
| Wu, CJ | 1 |
| Lee, HC | 1 |
| Chang, CM | 1 |
| Lin, CC | 1 |
| Lee, NY | 1 |
| Chu, WL | 1 |
| Hsieh, LY | 1 |
| Wang, YL | 1 |
| Lauderale, TL | 1 |
| Ko, NY | 1 |
| Ko, WC | 1 |
| Kiertiburanakul, S | 2 |
| Ratanasuwan, W | 1 |
| Kopetskie, HA | 1 |
| D'Avino, A | 1 |
| Di Giambenedetto, S | 1 |
| Fabbiani, M | 1 |
| Farina, S | 1 |
| Chandrashekar, UK | 1 |
| Acharya, V | 1 |
| Varghese, GK | 1 |
| Rao, L | 1 |
| Khan, Z | 2 |
| Ahmad, S | 1 |
| Joseph, L | 1 |
| Chandy, R | 1 |
| Khayhan, K | 1 |
| Hagen, F | 1 |
| Wahyuningsih, R | 1 |
| Chakrabarti, A | 1 |
| Chowdhary, A | 1 |
| Ikeda, R | 1 |
| Taj-Aldeen, SJ | 1 |
| Imran, D | 1 |
| Sjam, R | 1 |
| Sriburee, P | 1 |
| Chaicumpar, K | 1 |
| Ingviya, N | 1 |
| Mouton, JW | 2 |
| Curfs-Breuker, I | 1 |
| Boekhout, T | 1 |
| Meis, JF | 1 |
| Klaassen, CH | 1 |
| St Clair, K | 1 |
| Maguire, JD | 1 |
| Moris, DV | 1 |
| Melhem, MSC | 1 |
| Martins, MA | 1 |
| Souza, LR | 1 |
| Kacew, S | 1 |
| Szeszs, MW | 1 |
| Carvalho, LR | 1 |
| Pimenta-Rodrigues, MV | 1 |
| Berghs, HAM | 1 |
| Mendes, RP | 1 |
| Meya, BD | 1 |
| Mayanja-Kizza, H | 1 |
| Wiesner, LD | 1 |
| Bohjanen, P | 1 |
| R Boulware, RD | 1 |
| Kakuda, TN | 1 |
| Van Solingen-Ristea, R | 1 |
| Aharchi, F | 1 |
| Smedt, GD | 1 |
| Witek, J | 1 |
| Nijs, S | 1 |
| Vyncke, V | 1 |
| Hoetelmans, RM | 2 |
| Martinez, M | 3 |
| López-Ribot, JL | 7 |
| Kirkpatrick, WR | 7 |
| Coco, BJ | 1 |
| Bachmann, SP | 2 |
| Patterson, TF | 9 |
| Koks, CH | 5 |
| Crommentuyn, KM | 2 |
| Mathôt, RA | 2 |
| Mulder, JW | 2 |
| Meenhorst, PL | 5 |
| Beijnen, JH | 5 |
| Bult, A | 2 |
| Bussaratid, V | 1 |
| Tansupasawasdikul, S | 1 |
| Simpson, A | 1 |
| Pitisuttithum, P | 1 |
| Phonrat, B | 1 |
| Howe, P | 1 |
| White, NJ | 1 |
| Barchiesi, F | 3 |
| Maracci, M | 1 |
| Radi, B | 1 |
| Arzeni, D | 2 |
| Baldassarri, I | 1 |
| Giacometti, A | 1 |
| Scalise, G | 2 |
| Mathew, G | 1 |
| Smedema, M | 1 |
| Wheat, LJ | 2 |
| Goldman, M | 3 |
| Vargas, K | 1 |
| Srikantha, R | 1 |
| Holke, A | 1 |
| Sifri, T | 1 |
| Morris, R | 1 |
| Joly, S | 1 |
| Winter, HR | 2 |
| Trapnell, CB | 3 |
| Slattery, JT | 2 |
| Jacobson, M | 2 |
| Greenspan, DL | 2 |
| Hooton, TM | 2 |
| Unadkat, JD | 2 |
| de Wet, N | 1 |
| Llanos-Cuentas, A | 1 |
| Suleiman, J | 1 |
| Baraldi, E | 1 |
| Krantz, EF | 1 |
| Della Negra, M | 1 |
| Diekmann-Berndt, H | 1 |
| Buscemi, L | 1 |
| Arechavala, A | 1 |
| Negroni, R | 2 |
| McDonald, LC | 1 |
| Hsiao, CF | 1 |
| Cheng, HH | 2 |
| Ho, YA | 1 |
| Martínez-Baltanás, A | 1 |
| Cuadrado, JM | 1 |
| Jover, F | 1 |
| Roig, P | 3 |
| Tekeli, A | 1 |
| Koyuncu, E | 1 |
| Dolapci, I | 1 |
| Guven, GS | 1 |
| Sahin, GO | 1 |
| Uzun, O | 1 |
| Sánchez-Vargas, LO | 1 |
| Ortiz-López, NG | 1 |
| Villar, M | 1 |
| Moragues, MD | 1 |
| Cashat-Cruz, M | 1 |
| Tuculet, MA | 1 |
| Chumpathat, N | 1 |
| Chaovavanich, A | 1 |
| Hartung de Capriles, C | 1 |
| Mata-Essayag, S | 1 |
| Pérez, C | 1 |
| Colella, MT | 1 |
| Roselló, A | 1 |
| Olaizola, C | 1 |
| Abate, SM | 1 |
| Cloud, GA | 1 |
| Wade, KD | 1 |
| Reboli, AC | 1 |
| Fichtenbaum, CJ | 1 |
| Hafner, R | 1 |
| Powderly, WG | 3 |
| Stein, DK | 1 |
| Dismukes, WE | 1 |
| Bozzette, SA | 1 |
| Lopez-Rangel, E | 1 |
| Van Allen, MI | 1 |
| Wirojtananugoon, S | 1 |
| Pracharktam, R | 1 |
| Lilly, EA | 1 |
| Shetty, KV | 1 |
| Leigh, JE | 1 |
| Cheeks, C | 1 |
| Fidel, PL | 1 |
| Ribeiro, MA | 1 |
| Paula, CR | 1 |
| John, R | 1 |
| Cox, GM | 2 |
| Li, SY | 1 |
| Chen, KW | 1 |
| Chiou, CS | 1 |
| Wang, TH | 1 |
| Shetty, K | 1 |
| Garazzino, S | 1 |
| Tettoni, M | 1 |
| Calcagno, A | 1 |
| D'Avolio, A | 1 |
| Bonora, S | 1 |
| Di Perri, G | 1 |
| Dannaoui, E | 3 |
| Abdul, M | 1 |
| Arpin, M | 1 |
| Michel-Nguyen, A | 1 |
| Piens, MA | 2 |
| Favel, A | 1 |
| Legout, L | 1 |
| Assal, M | 1 |
| Rohner, P | 1 |
| Lew, D | 1 |
| Bernard, L | 1 |
| Hoffmeyer, P | 1 |
| Athichathanabadi, C | 1 |
| Uttayamakul, S | 1 |
| Phoorisri, T | 1 |
| Vilela, R | 1 |
| de Oliveira Teixeira, F | 1 |
| Vilela, L | 1 |
| Mendoza, L | 1 |
| Baixench, MT | 1 |
| Aoun, N | 1 |
| Desnos-Ollivier, M | 1 |
| Garcia-Hermoso, D | 1 |
| Bretagne, S | 1 |
| Ramires, S | 1 |
| Piketty, C | 1 |
| Wood, R | 1 |
| Hayes, M | 1 |
| Bekker, LG | 1 |
| Rodríguez-Tudela, JL | 1 |
| Almirante, B | 1 |
| Rodríguez-Pardo, D | 1 |
| Laguna, F | 1 |
| Donnelly, JP | 1 |
| Pahissa, A | 1 |
| Cuenca-Estrella, M | 1 |
| Depont, F | 1 |
| Vargas, F | 1 |
| Dutronc, H | 1 |
| Giauque, E | 1 |
| Ragnaud, JM | 1 |
| Galpérine, T | 1 |
| Abouelfath, A | 1 |
| Valentino, R | 1 |
| Dupon, M | 1 |
| Hébert, G | 1 |
| Moore, N | 1 |
| Antinori, S | 1 |
| Chottanapund, S | 1 |
| Singhasivanon, P | 1 |
| Kaewkungwal, J | 1 |
| Chamroonswasdi, K | 1 |
| Sing, Y | 1 |
| Ramdial, PK | 1 |
| Ibrahim, T | 1 |
| Oliveira, ER | 1 |
| Fothergill, A | 1 |
| Redding, SW | 2 |
| Apisarnthanarak, A | 1 |
| Mundy, LM | 1 |
| McClelland, RS | 1 |
| Richardson, BA | 1 |
| Hassan, WM | 1 |
| Chohan, V | 1 |
| Lavreys, L | 1 |
| Mandaliya, K | 1 |
| Kiarie, J | 1 |
| Jaoko, W | 1 |
| Ndinya-Achola, JO | 1 |
| Baeten, JM | 1 |
| Kurth, AE | 1 |
| Holmes, KK | 1 |
| Tett, S | 1 |
| Moore, S | 1 |
| Ray, J | 1 |
| Viard, JP | 1 |
| Hennequin, C | 1 |
| Fortineau, N | 1 |
| Pertuiset, N | 1 |
| Rothschild, C | 1 |
| Zylberberg, H | 1 |
| Diz Dios, PD | 1 |
| Alvarez Alvarez, J | 1 |
| Fernández Feijoo, J | 1 |
| Castro Ferreiro, M | 1 |
| Flynn, PM | 1 |
| Cunningham, CK | 1 |
| Kerkering, T | 1 |
| San Jorge, AR | 1 |
| Peters, VB | 1 |
| Pitel, PA | 1 |
| Harris, J | 1 |
| Gilbert, G | 1 |
| Castagnaro, L | 1 |
| Robinson, P | 1 |
| Rosing, H | 1 |
| Johnson, EM | 1 |
| Warnock, DW | 1 |
| Luker, J | 1 |
| Porter, SR | 1 |
| Scully, C | 1 |
| Quagliarello, VJ | 1 |
| Viscoli, C | 1 |
| Horwitz, RI | 1 |
| Sabin, C | 1 |
| Pasi, J | 1 |
| Phillips, A | 1 |
| Elford, J | 1 |
| Janossy, G | 1 |
| Lee, C | 1 |
| Imbert-Bernard, C | 1 |
| Valentin, A | 1 |
| Bastide, JM | 1 |
| Teira, R | 1 |
| Greenspan, D | 2 |
| Sangeorzan, JA | 1 |
| Bradley, SF | 1 |
| He, X | 2 |
| Zarins, LT | 2 |
| Ridenour, GL | 1 |
| Tiballi, RN | 2 |
| Kauffman, CA | 2 |
| Colombo, AL | 1 |
| McGough, DA | 1 |
| Fothergill, AW | 3 |
| Rinaldi, MG | 5 |
| Marriott, DJ | 1 |
| Jones, PD | 1 |
| Hoy, JF | 1 |
| Speed, BR | 1 |
| Harkness, JL | 1 |
| Nightingale, SD | 2 |
| Jockusch, JD | 2 |
| Haslund, I | 1 |
| Cal, SX | 2 |
| Peterson, DM | 2 |
| Loss, SD | 2 |
| Thevenot, T | 1 |
| Colardelle, P | 1 |
| Chochon, M | 1 |
| Andrieu, J | 1 |
| Sahai, J | 1 |
| Gallicano, K | 1 |
| Pakuts, A | 1 |
| Cameron, DW | 1 |
| Pons, V | 1 |
| Debruin, M | 1 |
| Glatt, AE | 1 |
| Azón-Masoliver, A | 1 |
| Vilaplana, J | 1 |
| Tunkel, AR | 1 |
| Thomas, CY | 1 |
| Wispelwey, B | 1 |
| Goa, KL | 1 |
| Barradell, LB | 1 |
| Newton, JA | 1 |
| Tasker, SA | 1 |
| Bone, WD | 1 |
| Oldfield, EC | 1 |
| Olson, PE | 1 |
| Nguyen, MT | 1 |
| Wallace, MR | 1 |
| Narang, PK | 2 |
| Lavelle, JP | 1 |
| Quereda, C | 1 |
| Polanco, AM | 1 |
| Giner, C | 1 |
| Sánchez-Sousa, A | 1 |
| Pereira, E | 1 |
| Navas, E | 1 |
| Fortún, J | 1 |
| Guerrero, A | 1 |
| Baquero, F | 1 |
| Kalivas, J | 1 |
| Geletko, SM | 1 |
| Segarra, M | 1 |
| Mayer, KH | 1 |
| Fiore, TC | 1 |
| Bettencourt, FA | 1 |
| Flanigan, TP | 1 |
| Dudley, MN | 1 |
| Eichel, M | 1 |
| Just-Nübling, G | 2 |
| Helm, EB | 2 |
| Stille, W | 2 |
| Peloquin, CA | 1 |
| Nitta, AT | 1 |
| Burman, WJ | 1 |
| Brudney, KF | 1 |
| Miranda-Massari, JR | 1 |
| McGuinness, ME | 1 |
| Berning, SE | 1 |
| Gerena, GT | 1 |
| Heald, AE | 1 |
| Schell, WA | 1 |
| Bartlett, JA | 1 |
| Goetz, MB | 1 |
| Wilcox, CM | 1 |
| Alexander, LN | 1 |
| Clark, WS | 1 |
| Thompson, SE | 1 |
| Cartledge, JD | 1 |
| Midgley, J | 1 |
| Gazzard, BG | 1 |
| Schmidt-Westhausen, A | 2 |
| Trautmann, M | 3 |
| Moran, GP | 1 |
| Sullivan, DJ | 2 |
| Henman, MC | 2 |
| McCreary, CE | 1 |
| Harrington, BJ | 1 |
| Shanley, DB | 2 |
| Coleman, DC | 3 |
| Colin, S | 1 |
| Pichot, J | 1 |
| Martins, MD | 1 |
| Lozano-Chiu, M | 1 |
| Rex, JH | 1 |
| White, TC | 2 |
| Pfaller, MA | 1 |
| Smith, J | 1 |
| Tumbarello, M | 1 |
| Tacconelli, E | 1 |
| Caldarola, G | 1 |
| Morace, G | 1 |
| Cauda, R | 1 |
| Ortona, L | 1 |
| Balloul, E | 1 |
| Couderc, LJ | 1 |
| Molina, JM | 1 |
| Cahite, I | 1 |
| Wolff, M | 1 |
| Saimot, AG | 1 |
| Caubarrère, I | 1 |
| Tolnay, M | 1 |
| Elzi, M | 1 |
| Reusser, P | 1 |
| Valdez, H | 2 |
| Gripshover, BM | 2 |
| Salata, RA | 2 |
| Lederman, MM | 2 |
| Revankar, SG | 1 |
| Mcatee, RK | 4 |
| McCarthy, DI | 1 |
| Sanche, SE | 1 |
| Cantu, RA | 1 |
| Blomgren, J | 1 |
| Berggren, U | 1 |
| Jontell, M | 1 |
| Lee, LN | 1 |
| Sanglard, D | 2 |
| Bellibas, SE | 1 |
| Masiá Canuto, MM | 1 |
| Gutiérrez Rodero, F | 1 |
| Ortiz de la Tabla Ducasse, V | 1 |
| Martín González, C | 1 |
| Escolano Hortelano, CM | 1 |
| Mora Rufete, A | 1 |
| Martín Hidalgo, A | 1 |
| Perea, S | 4 |
| Xu, J | 1 |
| Ramos, AR | 1 |
| Vilgalys, R | 1 |
| Mitchell, TG | 1 |
| Schorling, SR | 1 |
| Kortinga, HC | 1 |
| Froschb, M | 1 |
| Mühlschlegel, FA | 1 |
| Jordan, MK | 1 |
| Polis, MA | 1 |
| Kelly, G | 1 |
| Masur, H | 1 |
| Piscitelli, SC | 1 |
| Martínez, E | 1 |
| García-Viejo, MA | 1 |
| Marcos, MA | 1 |
| Pérez-Cuevas, JB | 1 |
| Blanco, JL | 1 |
| Mallolas, J | 1 |
| Miró, JM | 1 |
| Gatell, JM | 1 |
| Adler, A | 1 |
| Glick, ME | 1 |
| Zuger, A | 1 |
| Mascolini, M | 1 |
| Wood, D | 1 |
| Burger, DM | 1 |
| Koopmans, PP | 1 |
| Samaranayake, YH | 1 |
| Tsang, PC | 1 |
| Wong, KH | 1 |
| Yeung, KW | 1 |
| Vazquez, JA | 1 |
| Peng, G | 1 |
| Steele-Moore, L | 1 |
| Schuman, P | 1 |
| Holloway, W | 1 |
| Neaton, JD | 1 |
| Ellepola, AN | 1 |
| Lin, AL | 1 |
| Johnson, DA | 1 |
| Lu, DL | 1 |
| Shi, Q | 1 |
| Yeh, CK | 1 |
| Santillán, RA | 1 |
| Calabrese, D | 1 |
| Abad, S | 1 |
| Moachon, L | 1 |
| Blanche, P | 1 |
| Bavoux, F | 1 |
| Sicard, D | 1 |
| Salmon-Céron, D | 1 |
| Boyle, BM | 1 |
| Forkin, C | 1 |
| Mulcahy, F | 1 |
| Keane, CT | 1 |
| Pizzo, G | 2 |
| Falconi Di Francesco, L | 1 |
| Giuliana, G | 1 |
| Milici, ME | 2 |
| D'Angelo, M | 1 |
| Giammanco, GM | 1 |
| Pecorella, S | 1 |
| Distefano, S | 1 |
| Pecoraro, V | 1 |
| Gonzalez, G | 1 |
| Sutton, DA | 1 |
| Wickes, BL | 1 |
| Dib, OP | 1 |
| Keller, SM | 1 |
| Swindells, S | 1 |
| Evans, S | 1 |
| Zackin, R | 1 |
| Haubrich, R | 1 |
| Balfour, HH | 1 |
| Del Arco, A | 1 |
| Prada, JL | 1 |
| de La Torre, J | 1 |
| Romualdo, L | 1 |
| Gamble, BA | 1 |
| Watson, DA | 1 |
| Manzone, CP | 1 |
| Baker, JE | 1 |
| Gallagher, PJ | 1 |
| Bennett, DE | 1 |
| Russell, RJ | 1 |
| Flint, SR | 1 |
| López-Dupla, M | 1 |
| Mora Sanz, P | 1 |
| Pintado García, V | 1 |
| Valencia Ortega, E | 1 |
| Uriol, PL | 1 |
| Khamashta, MA | 1 |
| Aguado, AG | 1 |
| Hernández, JA | 1 |
| Gonzalez-Moreno, M | 1 |
| Llibre, JM | 1 |
| Aloy, A | 1 |
| Casan, CM | 1 |
| Pradier, C | 1 |
| Bernard, E | 1 |
| Lubick, C | 1 |
| Toussaint-Gari, M | 1 |
| Pinier, Y | 1 |
| Durant, J | 1 |
| Mondain, V | 1 |
| Le Fichoux, Y | 1 |
| Dellamonica, P | 1 |
| Carrasco, R | 2 |
| Salavert, M | 2 |
| Nieto, A | 2 |
| Bernacer, B | 1 |
| Rodríguez, M | 1 |
| Navarro, V | 2 |
| Garber, GE | 1 |
| Lewis, MA | 1 |
| Samaranyake, LP | 1 |
| Lamey, PJ | 1 |
| Tschechne, B | 1 |
| Brunkhorst, U | 1 |
| Dempe, S | 1 |
| Deicher, H | 1 |
| Gentschew, G | 1 |
| Meissner, K | 1 |
| Odewald, J | 1 |
| Staszewski, S | 1 |
| Brockmeyer, NH | 1 |
| Hantschke, D | 1 |
| Olbricht, T | 1 |
| Hengge, UA | 1 |
| Goos, M | 1 |
| van Gijn, R | 1 |
| Hazelager, WA | 1 |
| Underberg, WJ | 1 |
| Pottage, JC | 1 |
| Sha, BE | 1 |
| Blancard, A | 1 |
| Moulin-Traffort, J | 1 |
| Regli, P | 1 |
| Sarzier, JM | 1 |
| Quilici, M | 1 |
| Lim, SG | 1 |
| Lee, CA | 1 |
| Hales, M | 1 |
| O'Doherty, M | 1 |
| Winter, M | 1 |
| Kernoff, PB | 1 |
| Gill, SK | 1 |
| Martínez, A | 1 |
| Medina, E | 1 |
| Muñoz, P | 1 |
| Moreno, S | 1 |
| Garau, X | 1 |
| López Bernaldo de Quirós, JC | 1 |
| Berenguer, J | 1 |
| More, J | 1 |
| Bouza, E | 1 |
| Lucey, DR | 1 |
| Lucey, CR | 1 |
| Esposito, R | 1 |
| Castagna, A | 1 |
| Uberti Foppa, C | 1 |
| Chave, JP | 1 |
| Francioli, P | 1 |
| Hirschel, B | 1 |
| Glauser, MP | 1 |
| Thorsen, S | 1 |
| Mathiesen, LR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Comprehensive Diagnosis and Treatment Strategy for Opportunistic Fungal Infections in AIDS Patients[NCT05153005] | 600 participants (Anticipated) | Observational | 2021-04-01 | Recruiting | |||
| Operational Research for Cryptococcal Antigen Screening to Improve ART Survival[NCT01535469] | Phase 4 | 3,049 participants (Actual) | Interventional | 2012-07-01 | Completed | ||
| A Randomized Trial of Tamoxifen Combined With Amphotericin B and Fluconazole for Cryptococcal Meningitis[NCT03112031] | Phase 2 | 50 participants (Actual) | Interventional | 2017-10-10 | Completed | ||
| Adjunctive Sertraline for the Treatment of HIV-Associated Cryptococcal Meningitis[NCT01802385] | Phase 3 | 460 participants (Actual) | Interventional | 2015-03-09 | Completed | ||
| Oral Candidiasis in HIV Infected Individuals in Tanzania[NCT00553137] | Phase 4 | 220 participants (Actual) | Interventional | 2006-11-30 | Completed | ||
| A Phase II Randomized Trial of Amphotericin B Alone or Combined With Fluconazole in the Treatment of AIDS-Associated Cryptococcal Meningitis[NCT00145249] | Phase 2 | 143 participants (Actual) | Interventional | 2005-05-31 | Completed | ||
| Randomized Control Trial of Early vs Delayed ART in the Treatment of Cryptococcal Meningitis.[NCT00830856] | 54 participants (Actual) | Interventional | 2006-10-31 | Completed | |||
| A Phase I, Open-label Trial to Investigate the Pharmacokinetic Interaction Between TMC125 and Two Antifungal Agents (Fluconazole and Voriconazole), All at Steady-state in Healthy Subjects.[NCT00740389] | Phase 1 | 18 participants (Actual) | Interventional | 2008-09-30 | Completed | ||
| Effect of Fluconazole, Clarithromycin, and Rifabutin on the Pharmacokinetics of Sulfamethoxazole and Dapsone and Their Hydroxylamine Metabolites[NCT00000826] | Phase 1 | 48 participants | Interventional | Completed | |||
| DNA Sequencing of MDR TB in Eastern Siberia[NCT02508610] | 630 participants (Anticipated) | Observational | 2013-11-30 | Recruiting | |||
| A Phase II Trial to Describe the Pharmacokinetics, Safety and Efficacy of Pharmacogenetics-guided Dosing of Isoniazid in Patients With HIV-associated TB[NCT05124678] | Phase 2 | 40 participants (Anticipated) | Interventional | 2021-12-07 | Recruiting | ||
| A Randomized, Four-arm Open Label Phase Two-b Clinical Trial to Evaluate the Pharmacokinetics, Safety/Tolerability and Efficacy of High Dose Rifampicin in TB-HIV Co-infected Patients on Efavirenz- or Dolutegravir-based Antiretroviral Therapy[NCT03982277] | Phase 2 | 130 participants (Actual) | Interventional | 2019-04-30 | Completed | ||
| Incidence of Oral Candidiasis, Prevalence of Candida Dubliniensis in HIV Patients and In-vitro Azole Susceptibility. (I.C.O.N.I.C.)[NCT00692783] | 10 participants (Actual) | Observational | 2008-05-31 | Terminated (stopped due to Dr. Vindas completed his fellowship + low enrollment) | |||
| A Randomized Comparative Trial of Zidovudine (AZT) Versus 2',3'-Dideoxyinosine (ddI) Versus AZT Plus ddI in Symptomatic HIV-Infected Children[NCT00000637] | Phase 3 | 819 participants | Interventional | Completed | |||
| Randomized Comparative Study of Fluconazole Versus Clotrimazole Troches in the Prevention of Serious Fungal Infection in Patients With AIDS or Advanced AIDS-Related Complex. (A Nested Study of ACTG 081)[NCT00000676] | Phase 3 | 500 participants | Interventional | Completed | |||
| A Randomized Trial of Three Anti-Pneumocystis Agents Plus Zidovudine for the Primary Prevention of Serious Infections in Patients With Advanced HIV Infection[NCT00000991] | Phase 3 | 600 participants | Interventional | Completed | |||
| A Randomized, Prospective, Double-Blind Study Comparing Fluconazole With Placebo for Primary and Secondary Prophylaxis of Mucosal Candidiasis in HIV-Infected Women[NCT00000744] | 400 participants | Interventional | Completed | ||||
| A Phase IV Randomized Study of the Use of Fluconazole as Chronic Suppressive Therapy Versus Episodic Therapy in HIV Positive Subjects With Recurrent Oropharyngeal Candidiasis[NCT00000951] | Phase 4 | 948 participants | Interventional | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Center for Epidemiologic Studies in Depression (CES-D) scale at 14 weeks. CES-D scores are based on a 20 item survey with total scores ranging from 0 to 60. Higher scores suggest a greater presence of depressive symptoms. A CES-D score of 16 or higher is interpreted to indicate a risk for depression. (NCT01802385)
Timeframe: 14 weeks
| Intervention | score on a scale (Mean) |
|---|---|
| Placebo | 16.6 |
| Sertraline 400mg | 13.2 |
Number of participants with sterile cerebrospinal fluid at 2 weeks (NCT01802385)
Timeframe: 14 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 90 |
| Sertraline 400mg | 101 |
Event free survival of composite events of: death,central nervous system (CNS) cryptococcal-related paradoxical immune reconstitution inflammatory syndrome (IRIS) or culture-positive relapse. (NCT01802385)
Timeframe: 18 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 116 |
| Sertraline 400mg | 103 |
Cumulative incidence of central nervous system (CNS) cryptococcal-related paradoxical immune reconstitution inflammatory syndrome (IRIS) or culture-positive relapse (NCT01802385)
Timeframe: 18 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 9 |
| Sertraline 400mg | 5 |
Quantitative neurocognitive performance Z-score (QNPZ-8) at 14 weeks. The QNPZ-8 is a mean score of testing of 8 neurocognitive domains. Eqach domain is scaled based on a Z-score where the mean = 0 for the HIV-negative Ugandan population, accounting for age and educational status. Each +1 unit is one standard deviation better than the population norm. Each -1 unit is one standard deviation worse than the population norm. (NCT01802385)
Timeframe: 14 weeks
| Intervention | score (Mean) |
|---|---|
| Placebo | -1.4 |
| Sertraline 400mg | -1.3 |
Safety and tolerability of adjunctive sertraline (grade 4-5) adverse reactions (NCT01802385)
Timeframe: 18 weeks
| Intervention | events (Number) |
|---|---|
| Placebo | 121 |
| Sertraline 400mg | 141 |
18-week survival. The comparison will be between sertraline 400mg group and placebo (NCT01802385)
Timeframe: 18 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 125 |
| Sertraline 400mg | 109 |
To determine whether adjunctive sertraline will lead to a faster rate of fungal clearance from cerebrospinal fluid (CSF), as measured by early fungicidal activity (EFA) of clearance of the Cryptococcus colony forming units (cfu) per mL of CSF per day, compared to standard therapy alone. (NCT01802385)
Timeframe: 14 days
| Intervention | -log10 CFU/ml/day (Mean) | |
|---|---|---|
| General Linear Regression | Mixed-Effects Regression | |
| Placebo | 0.47 | 0.33 |
| Sertraline 400mg | .43 | .33 |
Neurological assessment by Mini-mental Status Exam (MMSE). This is collected as a continuous variable with values from 0-30; where lower scores indicate greater impairment. (NCT00145249)
Timeframe: Baseline and Day 14
| Intervention | Scores on a scale (Mean) |
|---|---|
| AmphoB Standard | 0.5 |
| AmphoB+Fluc400 | 2.1 |
| AmphoB + Fluc800 | 3.5 |
Neurological assessment by Mini-mental Status Exam (MMSE). This is collected as a continuous variable with values from 0-30; where lower scores indicate greater impairment. (NCT00145249)
Timeframe: Baseline and Day 168
| Intervention | Scores on a scale (Mean) |
|---|---|
| AmphoB Standard | 2.0 |
| AmphoB+Fluc400 | 2.8 |
| AmphoB + Fluc800 | 4.4 |
Neurological assessment by Mini-mental Status Exam (MMSE). This is collected as a continuous variable with values from 0-30; where lower scores indicate greater impairment. (NCT00145249)
Timeframe: Baseline and Day 42
| Intervention | Scores on a scale (Mean) |
|---|---|
| AmphoB Standard | 1.6 |
| AmphoB+Fluc400 | 1.8 |
| AmphoB + Fluc800 | 3.3 |
Neurological assessment by Mini-mental Status Exam (MMSE). This is collected as a continuous variable with values from 0-30; where lower scores indicate greater impairment. (NCT00145249)
Timeframe: Baseline and Day 70
| Intervention | Scores on a scale (Mean) |
|---|---|
| AmphoB Standard | 1.5 |
| AmphoB+Fluc400 | 2.2 |
| AmphoB + Fluc800 | 4.2 |
Mean days of hospitalization. Includes days subject was hospitalized prior to study enrollment for current hospital stay. (NCT00145249)
Timeframe: 7, 14, 42, and 70 days
| Intervention | Days (Mean) | |||
|---|---|---|---|---|
| Day 7 | Day 14 | Day 42 | Day 70 | |
| AmphoB + Fluc800 | 8.1 | 13.6 | 16.5 | 16.6 |
| AmphoB Standard | 8.9 | 15.4 | 16.3 | 16.7 |
| AmphoB+Fluc400 | 8.8 | 15.1 | 17.4 | 20.1 |
"Number of deaths occurring on study.~Day = Day relative to the first dose of study drug." (NCT00145249)
Timeframe: 14, 42, and 70 days
| Intervention | Subjects (Number) | ||||
|---|---|---|---|---|---|
| All Deaths | Day 1-14 | Day 15-42 | Day 43-70 | Day >70 | |
| AmphoB + Fluc800 | 9 | 1 | 1 | 5 | 2 |
| AmphoB Standard | 10 | 3 | 3 | 1 | 3 |
| AmphoB+Fluc400 | 8 | 2 | 2 | 2 | 2 |
"Events are reported by MedDRA Preferred Term.~Dose limiting toxicities include events that resulted in study drug being adjusted, interrupted, or discontinued." (NCT00145249)
Timeframe: Day 100
| Intervention | Events (Number) | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| All Events | Blood creatinine increased | Creatinine renal clearance decreased | Creatinine renal clearance increased | Renal failure | Renal failure acute | Azotaemia | Renal impairment | Nausea | Vomiting | Drug intolerance | Chills | Neutropenia | Hepatitis acute | Pneumonia | Dehydration | Respiratory failure | |
| AmphoB + Fluc800 | 14 | 1 | 2 | 2 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 1 | 1 | 1 |
| AmphoB Standard | 6 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 |
| AmphoB+Fluc400 | 7 | 1 | 1 | 0 | 2 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
"Events are reported by MedDRA Preferred Term.~Grade 3 - Severe. Incapacitating; inability to perform usual activities and daily tasks; significantly affects clinical status; requires therapeutic intervention.~Grade 4 - Life-threatening. AE is life-threatening.~Grade 5 - Death. AE causes death." (NCT00145249)
Timeframe: Day 100
| Intervention | Events (Number) | |||||
|---|---|---|---|---|---|---|
| Hypomagnesaemia | Hypokalaemia | Anaemia | Drug intolerance | Creatinine renal clearance increased | Psychotic disorder | |
| AmphoB + Fluc800 | 0 | 1 | 0 | 0 | 1 | 1 |
| AmphoB Standard | 2 | 0 | 1 | 1 | 0 | 0 |
| AmphoB+Fluc400 | 1 | 0 | 1 | 0 | 0 | 0 |
Treatment success is defined as a composite of the 3 mycologic and clinical measures: CSF culture conversion; neurologically stable or improved; and alive (NCT00145249)
Timeframe: 14, 42, and 70 days
| Intervention | Subjects (Number) | ||
|---|---|---|---|
| Day 14 - Success | Day 42 - Success | Day 70 - Success | |
| AmphoB + Fluc800 | 22 | 33 | 32 |
| AmphoB Standard | 19 | 33 | 33 |
| AmphoB+Fluc400 | 13 | 35 | 36 |
"Number of subjects reporting immune reconstitution inflammatory syndrome (IRIS) following treatment.~Day = Day relative to first dose of study drug" (NCT00145249)
Timeframe: 14, 42, and 70 days
| Intervention | Subjects (Number) | |||
|---|---|---|---|---|
| Day 1 through 70 | Day 1-14 | Day 15-42 | Day 43-70 | |
| AmphoB + Fluc800 | 1 | 0 | 0 | 1 |
| AmphoB Standard | 2 | 0 | 1 | 1 |
| AmphoB+Fluc400 | 0 | 0 | 0 | 0 |
Number of subjects that have a negative fungal culture at Baseline, Day 14, Day 42, and Day 70. (NCT00145249)
Timeframe: Baseline, 14, 42, and 70 days
| Intervention | Subjects (Number) | |||
|---|---|---|---|---|
| Baseline - Negative | Day 14 - Negative | Day 42 - Negative | Day 70 - Negative | |
| AmphoB + Fluc800 | 0 | 22 | 36 | 38 |
| AmphoB Standard | 0 | 20 | 35 | 36 |
| AmphoB+Fluc400 | 0 | 13 | 37 | 39 |
34 reviews available for fluconazole and HIV Coinfection
| Article | Year |
|---|---|
Vulvovaginal Candidiasis: A Review of the Evidence for the 2021 Centers for Disease Control and Prevention of Sexually Transmitted Infections Treatment Guidelines.
Topics: Antifungal Agents; Candida albicans; Candidiasis, Vulvovaginal; Centers for Disease Control and Prev | 2022 |
Refractory esophagitis caused by
Topics: Adult; Antifungal Agents; Brazil; Drug Resistance, Fungal; Esophagitis; Fluconazole; HIV Infections; | 2022 |
Treatment of Cryptococcal Meningitis: How Have We Got Here and Where are We Going?
Topics: Adult; Amphotericin B; Antifungal Agents; Fluconazole; Flucytosine; Glucocorticoids; HIV Infections; | 2022 |
An updated systematic review of HIV-associated cryptococcal meningitis treatment strategies.
Topics: Amphotericin B; Antifungal Agents; Drug Therapy, Combination; Fluconazole; Flucytosine; HIV Infectio | 2023 |
New Insights Into Cryptococcus Spp. Biology and Cryptococcal Meningitis.
Topics: Amphotericin B; Antifungal Agents; Antiretroviral Therapy, Highly Active; Cryptococcus; Drug Therapy | 2019 |
Cryptococcosis in pregnancy and the postpartum period: Case series and systematic review with recommendations for management.
Topics: Adolescent; Adult; Amphotericin B; Antifungal Agents; Clinical Trials as Topic; Cryptococcus neoform | 2020 |
Mortality from HIV-associated meningitis in sub-Saharan Africa: a systematic review and meta-analysis.
Topics: Adult; Africa South of the Sahara; Aged; Amphotericin B; Antifungal Agents; Female; Fluconazole; HIV | 2020 |
Treating progressive disseminated histoplasmosis in people living with HIV.
Topics: Amphotericin B; Anti-HIV Agents; Antifungal Agents; Cohort Studies; Deoxycholic Acid; Drug Administr | 2020 |
Colonic cryptococcosis as a rare presentation in HIV infection: a case report and review of the literature.
Topics: Adult; Amphotericin B; Antifungal Agents; Cryptococcosis; Cryptococcus neoformans; Female; Fluconazo | 2020 |
Strategies for the diagnosis and management of meningitis in HIV-infected adults in resource limited settings.
Topics: Adult; AIDS-Related Opportunistic Infections; Antifungal Agents; Fluconazole; HIV Infections; Humans | 2021 |
Long-term Mortality and Disability in Cryptococcal Meningitis: A Systematic Literature Review.
Topics: Antifungal Agents; Australia; Cryptococcus gattii; Cryptococcus neoformans; Disabled Persons; Flucon | 2018 |
Impact of Routine Cryptococcal Antigen Screening and Targeted Preemptive Fluconazole Therapy in Antiretroviral-naive Human Immunodeficiency Virus-infected Adults With CD4 Cell Counts <100/μL: A Systematic Review and Meta-analysis.
Topics: Adult; Aged; Aged, 80 and over; Antifungal Agents; CD4 Lymphocyte Count; Chemoprevention; Female; Fl | 2019 |
Early versus delayed antiretroviral treatment in HIV-positive people with cryptococcal meningitis.
Topics: AIDS-Related Opportunistic Infections; Amphotericin B; Anti-HIV Agents; Antifungal Agents; Cause of | 2018 |
Treatment for HIV-associated cryptococcal meningitis.
Topics: Acetazolamide; Acute Disease; Adult; Amphotericin B; Antifungal Agents; Developing Countries; Drug A | 2018 |
Leave no one behind: response to new evidence and guidelines for the management of cryptococcal meningitis in low-income and middle-income countries.
Topics: Africa; Amphotericin B; Antifungal Agents; Coinfection; Cryptococcus neoformans; Developing Countrie | 2019 |
Recent advances in managing HIV-associated cryptococcal meningitis.
Topics: Amphotericin B; Antifungal Agents; Fluconazole; Flucytosine; HIV Infections; Humans; Meningitis, Cry | 2019 |
Cryptococcal infections: changing epidemiology and implications for therapy.
Topics: Animals; Antifungal Agents; Cryptococcosis; Cryptococcus gattii; Cryptococcus neoformans; Fluconazol | 2013 |
Flucytosine and cryptococcosis: time to urgently address the worldwide accessibility of a 50-year-old antifungal.
Topics: Africa; AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Asia; Fluconazole; | 2013 |
Comparison of flucytosine and fluconazole combined with amphotericin B for the treatment of HIV-associated cryptococcal meningitis: a systematic review and meta-analysis.
Topics: Amphotericin B; Antifungal Agents; Coinfection; Drug Therapy, Combination; Fluconazole; Flucytosine; | 2014 |
[Cryptococcal meningitis].
Topics: Adult; Aged; Amphotericin B; Antifungal Agents; Cryptococcus neoformans; Female; Fluconazole; Flucyt | 2015 |
Physiological Differences in Cryptococcus neoformans Strains
Topics: Amphotericin B; Antifungal Agents; Cryptococcus neoformans; Drug Resistance, Fungal; Fluconazole; Fu | 2017 |
Treatment of acute cryptococcal meningitis in HIV infected adults, with an emphasis on resource-limited settings.
Topics: Acetazolamide; Acute Disease; Adult; Amphotericin B; Antifungal Agents; Antihypertensive Agents; Dev | 2008 |
Candidiasis (oropharyngeal).
Topics: Administration, Oral; Antifungal Agents; Candidiasis; Candidiasis, Oral; Fluconazole; HIV Infections | 2009 |
Treatment of cryptococcal meningitis in resource limited settings.
Topics: AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Developing Countries; Fluc | 2009 |
HIV: primary and secondary prophylaxis for opportunistic infections.
Topics: AIDS-Related Opportunistic Infections; Fluconazole; HIV Infections; Humans; Isoniazid; Opportunistic | 2010 |
Candidiasis (oropharyngeal).
Topics: Administration, Oral; Antifungal Agents; Candidiasis, Oral; Fluconazole; HIV Infections; Humans; Oro | 2012 |
Itraconazole solution: summary of pharmacokinetic features and review of activity in the treatment of fluconazole-resistant oral candidosis in HIV-infected persons.
Topics: Administration, Oral; AIDS-Related Opportunistic Infections; Antifungal Agents; Candida; Candidiasis | 2002 |
Treatment of oropharyngeal candidiasis in HIV-positive patients.
Topics: Administration, Oral; Administration, Topical; Antifungal Agents; Candidiasis, Oral; CD4-Positive T- | 1994 |
Candida prosthetic arthritis: report of a case treated with fluconazole and review of the literature.
Topics: Adult; Arthritis, Infectious; Candidiasis; Fluconazole; HIV Infections; Humans; Knee Prosthesis; Mal | 1993 |
Fluconazole. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Opportunistic Infections; Animals; Antifungal Agent | 1995 |
The role of Candida dubliniensis in oral candidiasis in human immunodeficiency virus-infected individuals.
Topics: Antifungal Agents; Candida; Candidiasis, Oral; Drug Resistance, Microbial; Fluconazole; Genotype; HI | 2000 |
Current approach to the acute management of cryptococcal infections.
Topics: AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; CD4 Lymphocyte Count; Cryp | 2000 |
Fluconazole: a new option in the treatment of Candida mucositis and esophageal candidiasis.
Topics: Candidiasis; Candidiasis, Oral; Esophageal Diseases; Fluconazole; HIV Infections; Humans; Mouth Muco | 1992 |
Diagnosis and treatment of oral candidosis.
Topics: Antifungal Agents; Candidiasis, Oral; Chronic Disease; Fluconazole; HIV Infections; Humans; Immune T | 1991 |
40 trials available for fluconazole and HIV Coinfection
| Article | Year |
|---|---|
Single-Dose Liposomal Amphotericin B Treatment for Cryptococcal Meningitis.
Topics: Administration, Oral; Africa South of the Sahara; AIDS-Related Opportunistic Infections; Amphoterici | 2022 |
How Applicable Is the Single-Dose AMBITION Regimen for Human Immunodeficiency Virus-Associated Cryptococcal Meningitis to High-Income Settings?
Topics: Antifungal Agents; Drug Therapy, Combination; Fluconazole; Flucytosine; HIV; HIV Infections; Humans; | 2023 |
Higher Dose Oral Fluconazole for the Treatment of AIDS-related Cryptococcal Meningitis (HIFLAC)-report of A5225, a multicentre, phase I/II, two-stage, dose-finding, safety, tolerability and efficacy randomised, amphotericin B-controlled trial of the AIDS
Topics: Acquired Immunodeficiency Syndrome; Adult; Amphotericin B; Antifungal Agents; Drug Therapy, Combinat | 2023 |
Effect of oral fluconazole 1200 mg/day on QT interval in African adults with HIV-associated cryptococcal meningitis.
Topics: Adult; Africa; Antifungal Agents; Fluconazole; Heart Conduction System; HIV Infections; Humans; Meni | 2018 |
Reflexive Laboratory-Based Cryptococcal Antigen Screening and Preemptive Fluconazole Therapy for Cryptococcal Antigenemia in HIV-Infected Individuals With CD4 <100 Cells/µL: A Stepped-Wedge, Cluster-Randomized Trial.
Topics: Adult; AIDS-Related Opportunistic Infections; Antifungal Agents; Antigens, Fungal; CD4 Lymphocyte Co | 2019 |
Pregnancy in HIV clinical trials in Sub Saharan Africa: failure of consent or contraception?
Topics: Adult; Africa South of the Sahara; Antifungal Agents; Condoms; Condoms, Female; Contraception; Contr | 2013 |
Increased Antifungal Drug Resistance in Clinical Isolates of Cryptococcus neoformans in Uganda.
Topics: Amphotericin B; Antifungal Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Coinfection; Cr | 2015 |
Amphotericin B: the higher the dose, the higher the toxicity.
Topics: Amphotericin B; Antifungal Agents; Dose-Response Relationship, Drug; Fluconazole; Flucytosine; HIV I | 2008 |
Single-dose fluconazole versus standard 2-week therapy for oropharyngeal candidiasis in HIV-infected patients: a randomized, double-blind, double-dummy trial.
Topics: Adult; Aged; Antifungal Agents; Candidiasis, Oral; Double-Blind Method; Female; Fluconazole; HIV Inf | 2008 |
A phase II randomized trial of amphotericin B alone or combined with fluconazole in the treatment of HIV-associated cryptococcal meningitis.
Topics: Adult; Amphotericin B; Antifungal Agents; Cerebrospinal Fluid; Female; Fluconazole; HIV Infections; | 2009 |
Monitoring and impact of fluconazole serum and cerebrospinal fluid concentration in HIV-associated cryptococcal meningitis-infected patients.
Topics: Amphotericin B; Anti-HIV Agents; Antifungal Agents; Antiretroviral Therapy, Highly Active; Biologica | 2010 |
Co-administration of fluconazole increases nevirapine concentrations in HIV-infected Ugandans.
Topics: Adult; Anti-HIV Agents; Antifungal Agents; Cryptococcosis; Drug Interactions; Female; Fluconazole; H | 2010 |
Combination flucytosine and high-dose fluconazole compared with fluconazole monotherapy for the treatment of cryptococcal meningitis: a randomized trial in Malawi.
Topics: Administration, Oral; Adult; Aged; AIDS-Related Opportunistic Infections; Antifungal Agents; Cerebro | 2010 |
Early versus delayed initiation of antiretroviral therapy for concurrent HIV infection and cryptococcal meningitis in sub-saharan Africa.
Topics: Adult; Anti-HIV Agents; Antifungal Agents; Antiretroviral Therapy, Highly Active; Female; Fluconazol | 2010 |
Pharmacokinetics and short-term safety of etravirine in combination with fluconazole or voriconazole in HIV-negative volunteers.
Topics: Adolescent; Adult; Anti-HIV Agents; Antifungal Agents; Aryl Hydrocarbon Hydroxylases; Cross-Over Stu | 2013 |
The effect of clarithromycin, fluconazole, and rifabutin on sulfamethoxazole hydroxylamine formation in individuals with human immunodeficiency virus infection (AACTG 283).
Topics: Adult; Anti-Infective Agents; Area Under Curve; CD4 Lymphocyte Count; Clarithromycin; Drug Interacti | 2004 |
A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients.
Topics: Adolescent; Adult; Aged; AIDS-Related Opportunistic Infections; Antifungal Agents; Candidiasis; Doub | 2004 |
The effect of clarithromycin, fluconazole, and rifabutin on dapsone hydroxylamine formation in individuals with human immunodeficiency virus infection (AACTG 283).
Topics: Adult; Algorithms; Anti-Bacterial Agents; Antifungal Agents; Area Under Curve; CD4 Lymphocyte Count; | 2004 |
A randomized study of the use of fluconazole in continuous versus episodic therapy in patients with advanced HIV infection and a history of oropharyngeal candidiasis: AIDS Clinical Trials Group Study 323/Mycoses Study Group Study 40.
Topics: Adult; Aged; AIDS-Related Opportunistic Infections; Antifungal Agents; Candidiasis, Oral; CD4 Lympho | 2005 |
Improvement of vaginal health for Kenyan women at risk for acquisition of human immunodeficiency virus type 1: results of a randomized trial.
Topics: Adolescent; Adult; Anti-Infective Agents; Antifungal Agents; Candidiasis, Vulvovaginal; Female; Fluc | 2008 |
Fluconazole response patterns in HIV-infected patients with oropharyngeal candidiasis.
Topics: Candida albicans; Candidiasis, Oral; CD4 Lymphocyte Count; Colony Count, Microbial; Fluconazole; HIV | 1995 |
Oropharyngeal candidiasis in immunocompromised children: a randomized, multicenter study of orally administered fluconazole suspension versus nystatin. The Multicenter Fluconazole Study Group.
Topics: Administration, Oral; Adolescent; Candidiasis, Oral; Child; Child, Preschool; Double-Blind Method; D | 1995 |
Emergence of azole drug resistance in Candida species from HIV-infected patients receiving prolonged fluconazole therapy for oral candidosis.
Topics: Antifungal Agents; Azoles; Candida albicans; Candidiasis, Oral; Drug Resistance, Microbial; Fluconaz | 1995 |
Epidemiology of oral candidiasis in HIV-infected patients: colonization, infection, treatment, and emergence of fluconazole resistance.
Topics: Adult; AIDS-Related Opportunistic Infections; Candida; Candidiasis; Clotrimazole; Drug Resistance, M | 1994 |
Fluconazole once a week as secondary prophylaxis against oropharyngeal candidiasis in HIV-infected patients. A double-blind placebo-controlled study.
Topics: Adult; Alkaline Phosphatase; Candidiasis, Oral; Double-Blind Method; Drug Administration Schedule; F | 1993 |
Effect of fluconazole on zidovudine pharmacokinetics in patients infected with human immunodeficiency virus.
Topics: Adult; Analysis of Variance; Drug Therapy, Combination; Fluconazole; HIV Infections; Humans; Male; Z | 1994 |
Therapy for oropharyngeal candidiasis in HIV-infected patients: a randomized, prospective multicenter study of oral fluconazole versus clotrimazole troches. The Multicenter Study Group.
Topics: Administration, Oral; Adult; AIDS-Related Opportunistic Infections; Candidiasis, Oral; Clotrimazole; | 1993 |
Increased plasma rifabutin levels with concomitant fluconazole therapy in HIV-infected patients.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Bacterial Agents; Antifungal Agents; Antiviral Ag | 1996 |
Electronic compliance assessment of antifungal prophylaxis for human immunodeficiency virus-infected women.
Topics: Adult; AIDS-Related Opportunistic Infections; Antifungal Agents; Candidiasis, Chronic Mucocutaneous; | 1996 |
Low antituberculosis drug concentrations in patients with AIDS.
Topics: Adult; Anti-HIV Agents; Antifungal Agents; Antitubercular Agents; Drug Interactions; Female; Flucona | 1996 |
Low antituberculosis drug concentrations in patients with AIDS.
Topics: Adult; Anti-HIV Agents; Antifungal Agents; Antitubercular Agents; Drug Interactions; Female; Flucona | 1996 |
Low antituberculosis drug concentrations in patients with AIDS.
Topics: Adult; Anti-HIV Agents; Antifungal Agents; Antitubercular Agents; Drug Interactions; Female; Flucona | 1996 |
Low antituberculosis drug concentrations in patients with AIDS.
Topics: Adult; Anti-HIV Agents; Antifungal Agents; Antitubercular Agents; Drug Interactions; Female; Flucona | 1996 |
Low antituberculosis drug concentrations in patients with AIDS.
Topics: Adult; Anti-HIV Agents; Antifungal Agents; Antitubercular Agents; Drug Interactions; Female; Flucona | 1996 |
Low antituberculosis drug concentrations in patients with AIDS.
Topics: Adult; Anti-HIV Agents; Antifungal Agents; Antitubercular Agents; Drug Interactions; Female; Flucona | 1996 |
Low antituberculosis drug concentrations in patients with AIDS.
Topics: Adult; Anti-HIV Agents; Antifungal Agents; Antitubercular Agents; Drug Interactions; Female; Flucona | 1996 |
Low antituberculosis drug concentrations in patients with AIDS.
Topics: Adult; Anti-HIV Agents; Antifungal Agents; Antitubercular Agents; Drug Interactions; Female; Flucona | 1996 |
Low antituberculosis drug concentrations in patients with AIDS.
Topics: Adult; Anti-HIV Agents; Antifungal Agents; Antitubercular Agents; Drug Interactions; Female; Flucona | 1996 |
Fluconazole compared with endoscopy for human immunodeficiency virus-infected patients with esophageal symptoms.
Topics: Adult; Antifungal Agents; Candidiasis; Cost-Benefit Analysis; Esophageal Diseases; Esophagitis; Esop | 1996 |
Fluconazole versus nystatin in the treatment of oral candidosis.
Topics: Administration, Oral; Adult; Aged; Antifungal Agents; Candidiasis, Oral; Capsules; Dentures; Erythem | 1998 |
Effects of fluconazole and clarithromycin on rifabutin and 25-O-desacetylrifabutin pharmacokinetics.
Topics: Adult; Anti-Bacterial Agents; Antibiotics, Antitubercular; Antifungal Agents; Clarithromycin; Drug I | 2000 |
The effect of fluconazole on ritonavir and saquinavir pharmacokinetics in HIV-1-infected individuals.
Topics: Administration, Oral; Adult; Anti-HIV Agents; Antifungal Agents; Area Under Curve; Biological Availa | 2001 |
Evolution of antifungal susceptibility among Candida species isolates recovered from human immunodeficiency virus-infected women receiving fluconazole prophylaxis.
Topics: Adult; AIDS-Related Opportunistic Infections; Antifungal Agents; Candida; Candidiasis; Double-Blind | 2001 |
Predictive value of HIV-1 viral load on risk for opportunistic infection.
Topics: Adult; AIDS-Related Opportunistic Infections; Antifungal Agents; Antiretroviral Therapy, Highly Acti | 2002 |
[Fluconazole in therapy of candidiasis of the oropharyngeal space in patients with HIV infection. Results of an open multicenter study of assessing the effectiveness and tolerance of fluconazole].
Topics: Administration, Oral; Adult; Aged; Candidiasis, Oral; Female; Fluconazole; HIV Infections; Humans; I | 1991 |
Fluconazole prophylaxis of recurrent oral candidiasis in HIV-positive patients.
Topics: Acquired Immunodeficiency Syndrome; Candidiasis, Oral; Chronic Disease; Drug Administration Schedule | 1991 |
Fluconazole for oropharyngeal candidiasis in anti-HIV positive haemophiliacs.
Topics: Adolescent; Adult; Aged; Candidiasis; Candidiasis, Oral; Child; Double-Blind Method; Female; Flucona | 1991 |
[Multicenter study of fluconazole in the treatment of oropharyngeal candidiasis in immunodepressed patients].
Topics: Adult; Candidiasis, Oral; Female; Fluconazole; HIV Infections; Humans; Immunologic Deficiency Syndro | 1990 |
225 other studies available for fluconazole and HIV Coinfection
| Article | Year |
|---|---|
Cross-resistance to medical and agricultural azole drugs in yeasts from the oropharynx of human immunodeficiency virus patients and from environmental Bavarian vine grapes.
Topics: AIDS-Related Opportunistic Infections; Antifungal Agents; Azoles; Candida albicans; Candidiasis, Ora | 2007 |
Autoimmune diseases in HIV-negative cryptococcal meningitis.
Topics: Antifungal Agents; Autoimmune Diseases; Fluconazole; HIV Infections; Humans; Meningitis, Cryptococca | 2021 |
High Prevalence of HIV-Related Cryptococcosis and Increased Resistance to Fluconazole of the
Topics: Antifungal Agents; China; Cryptococcosis; Cryptococcus gattii; Cryptococcus neoformans; Drug Resista | 2021 |
In vitro synergistic effect of minocycline combined with antifungals against Cryptococcus neoformans.
Topics: Antifungal Agents; Cryptococcosis; Cryptococcus neoformans; Fluconazole; HIV Infections; Humans; Mic | 2022 |
Cost-effectiveness of single-dose AmBisome pre-emptive treatment for the prevention of cryptococcal meningitis in African low and middle-income countries.
Topics: Amphotericin B; Animals; Antifungal Agents; Antigens, Fungal; CD4 Lymphocyte Count; Cost-Benefit Ana | 2022 |
In vitro Azole antifungals susceptibility of Candida spp. isolates from HIV-infected patients with periodontitis.
Topics: Antifungal Agents; Azoles; Candida; Candida albicans; Candida tropicalis; Drug Resistance, Fungal; F | 2022 |
Outcomes of flucytosine-containing combination treatment for cryptococcal meningitis in a South African national access programme: a cross-sectional observational study.
Topics: Adult; Antifungal Agents; Cross-Sectional Studies; Cryptococcosis; Female; Fluconazole; Flucytosine; | 2022 |
Molecular type distribution and fluconazole susceptibility of clinical Cryptococcus gattii isolates from South African laboratory-based surveillance, 2005-2013.
Topics: Cryptococcosis; Cryptococcus gattii; Cryptococcus neoformans; Fluconazole; Genotype; HIV Infections; | 2022 |
Comparison of amphotericin B deoxycholate in combination with either flucytosine or fluconazole, and voriconazole plus flucytosine for the treatment of HIV-associated cryptococcal meningitis: a prospective multicenter study in China.
Topics: Amphotericin B; Antifungal Agents; Cohort Studies; Deoxycholic Acid; Drug Combinations; Drug Therapy | 2022 |
A post-mortem analysis of tenofovir, lamivudine, efavirenz and fluconazole penetration in female genital tissues.
Topics: Anti-HIV Agents; Autopsy; Benzoxazines; Chromatography, Liquid; Female; Fluconazole; Genitalia, Fema | 2022 |
Induction therapy with high-dose fluconazole plus flucytosine for human immunodeficiency virus-uninfected cryptococcal meningitis patients: Feasible or not?
Topics: Antifungal Agents; Drug Therapy, Combination; Fluconazole; Flucytosine; HIV; HIV Infections; Humans; | 2023 |
The acceptability of the AMBITION-cm treatment regimen for HIV-associated cryptococcal meningitis: Findings from a qualitative methods study of participants and researchers in Botswana and Uganda.
Topics: Antifungal Agents; Botswana; Drug Therapy, Combination; Fluconazole; Flucytosine; HIV Infections; Hu | 2022 |
Cryptococcal meningitis with atypical paradoxical inflammatory reactions after antifungal treatment in acquired immune deficiency syndrome: A case report.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Ag | 2023 |
Cryptococcal meningitis with atypical paradoxical inflammatory reactions after antifungal treatment in acquired immune deficiency syndrome: A case report.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Ag | 2023 |
Cryptococcal meningitis with atypical paradoxical inflammatory reactions after antifungal treatment in acquired immune deficiency syndrome: A case report.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Ag | 2023 |
Cryptococcal meningitis with atypical paradoxical inflammatory reactions after antifungal treatment in acquired immune deficiency syndrome: A case report.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Ag | 2023 |
Cryptococcal meningitis with atypical paradoxical inflammatory reactions after antifungal treatment in acquired immune deficiency syndrome: A case report.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Ag | 2023 |
Cryptococcal meningitis with atypical paradoxical inflammatory reactions after antifungal treatment in acquired immune deficiency syndrome: A case report.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Ag | 2023 |
Cryptococcal meningitis with atypical paradoxical inflammatory reactions after antifungal treatment in acquired immune deficiency syndrome: A case report.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Ag | 2023 |
Cryptococcal meningitis with atypical paradoxical inflammatory reactions after antifungal treatment in acquired immune deficiency syndrome: A case report.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Ag | 2023 |
Cryptococcal meningitis with atypical paradoxical inflammatory reactions after antifungal treatment in acquired immune deficiency syndrome: A case report.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Ag | 2023 |
Gene expression profiles of ERG11, MDR1 and AFR1 in Cryptococcus neoformans var.grubbi from HIV patients
Topics: Cryptococcus neoformans; Fluconazole; HIV Infections; Humans; Retrospective Studies | 2022 |
Gene expression profiles of ERG11, MDR1 and AFR1 in Cryptococcus neoformans var.grubbi from HIV patients
Topics: Cryptococcus neoformans; Fluconazole; HIV Infections; Humans; Retrospective Studies | 2022 |
Gene expression profiles of ERG11, MDR1 and AFR1 in Cryptococcus neoformans var.grubbi from HIV patients
Topics: Cryptococcus neoformans; Fluconazole; HIV Infections; Humans; Retrospective Studies | 2022 |
Gene expression profiles of ERG11, MDR1 and AFR1 in Cryptococcus neoformans var.grubbi from HIV patients
Topics: Cryptococcus neoformans; Fluconazole; HIV Infections; Humans; Retrospective Studies | 2022 |
Antifungal drug resistance in oral Candida isolates from HIV-infected and healthy individuals and efficacy of chitosan as an alternative antifungal agent.
Topics: Amphotericin B; Antifungal Agents; Candida; Chitosan; Drug Resistance, Fungal; Fluconazole; HIV Infe | 2023 |
Low level of antifungal resistance in Candida species recovered from Iranian HIV-associated oral infection.
Topics: Antifungal Agents; Candida; Candidiasis, Oral; Drug Resistance, Fungal; Fluconazole; HIV Infections; | 2023 |
Correlation of antifungal susceptibility and sequence types within Cryptococcus neoformans VNI from HIV patients, and ERG11 gene polymorphism.
Topics: Amphotericin B; Antifungal Agents; Cryptococcosis; Cryptococcus neoformans; Democratic Republic of t | 2023 |
In vitro sensitivity of Malassezia furfur isolates from HIV-positive and negative patients to antifungal agents
Topics: Amphotericin B; Animals; Antifungal Agents; Dermatitis, Seborrheic; Fluconazole; HIV Infections; Hum | 2023 |
Pharmacokinetics-pharmacodynamics of sertraline as an antifungal in HIV-infected Ugandans with cryptococcal meningitis.
Topics: Adult; Amphotericin B; Antifungal Agents; Brain; Cerebrospinal Fluid; Female; Fluconazole; HIV Infec | 2019 |
Oesophageal tuberculosis with concomitant candidiasis: a rare cause of dysphagia.
Topics: Antifungal Agents; Antitubercular Agents; Candidiasis; Deglutition Disorders; Esophageal Diseases; F | 2019 |
[Forty cases of neuromeningeal cryptococcosis diagnosed at the Mycology-Parasitology Department of the Ibn Sina hospital in Rabat, over a 21-year period].
Topics: Adult; Aged; AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Cryptococcus | 2019 |
Cryptococcus genetic diversity and mixed infections in Ivorian HIV patients: A follow up study.
Topics: Adult; Amphotericin B; Antifungal Agents; Coinfection; Cryptococcosis; Cryptococcus; Cryptococcus ne | 2019 |
A case report of catheter-related bloodstream infection due to Trichosporon coremiiforme in a patient with secondary neutropenia to HIV.
Topics: AIDS-Related Opportunistic Infections; Amphotericin B; Antitubercular Agents; Bacteremia; Catheter-R | 2020 |
Cerebrospinal Fluid Early Fungicidal Activity as a Surrogate Endpoint for Cryptococcal Meningitis Survival in Clinical Trials.
Topics: Amphotericin B; Antifungal Agents; Biomarkers; Cerebrospinal Fluid; Fluconazole; HIV Infections; Hum | 2020 |
Prevalence and mortality of cryptococcal disease in adults with advanced HIV in an urban tertiary hospital in Sierra Leone: a prospective study.
Topics: Adult; AIDS-Related Opportunistic Infections; Antifungal Agents; Antigens, Fungal; Cross-Sectional S | 2020 |
Case Report: A Case of Severe Cryptococcal Immune Reconstitution Inflammatory Syndrome Presenting with Brain and Intradural Abscesses in an HIV Patient.
Topics: Acquired Immunodeficiency Syndrome; Amphotericin B; Anti-Inflammatory Agents; Anti-Retroviral Agents | 2020 |
Cryptococcal Meningitis: A Rare Complication in HIV-Negative Patients with Nephrotic Syndrome in A Chinese Teaching Hospital.
Topics: Antifungal Agents; China; Fluconazole; HIV Infections; Hospitals, Teaching; Humans; Meningitis, Cryp | 2020 |
Innovations for prevention and care of oral candidiasis in HIV-infected individuals: Are they available?-A workshop report.
Topics: Antifungal Agents; Candidiasis, Oral; Fluconazole; HIV Infections; Humans | 2020 |
HIV-Associated Cryptococcal Meningitis Patients Treated with Amphotericin B Deoxycholate Plus Flucytosine under Routine Care Conditions in a Referral Center in São Paulo, Brazil.
Topics: Adult; Amphotericin B; Antifungal Agents; Brazil; Deoxycholic Acid; Drug Combinations; Drug Therapy, | 2021 |
Genetic diversity and antifungal susceptibility of Candida albicans isolates from Iranian HIV-infected patients with oral candidiasis.
Topics: Antifungal Agents; Candida; Candida albicans; Candidiasis, Oral; Fluconazole; Genetic Variation; HIV | 2021 |
Laboratory Reflex and Clinic-Based Point-of-Care Cryptococcal Antigen Screening for Preventing Meningitis and Mortality Among People Living With HIV.
Topics: Adult; Antifungal Agents; Antigens, Fungal; Cryptococcus; Female; Fluconazole; HIV Infections; Human | 2021 |
Not What It Seems: Obstructive Jaundice in an HIV-Positive Patient.
Topics: Abdominal Abscess; Anti-Bacterial Agents; Antifungal Agents; Candidiasis, Invasive; Diagnosis, Diffe | 2021 |
Factors associated with early mycological clearance in HIV-associated cryptococcal meningitis.
Topics: Adult; AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Colony Count, Micro | 2017 |
Primary Prophylaxis for Cryptococcosis With Fluconazole in Human Immunodeficiency Virus-Infected Patients With CD4 T-Cell Counts <100 Cells/µL and Receiving Antiretroviral Therapy.
Topics: Adult; AIDS-Related Opportunistic Infections; Antifungal Agents; Antiretroviral Therapy, Highly Acti | 2017 |
Prevalence of cryptococcal infection among advanced HIV patients in Argentina using lateral flow immunoassay.
Topics: Adult; Antigens, Fungal; Argentina; Female; Fluconazole; HIV Infections; Humans; Immunoassay; Male; | 2017 |
Are fluconazole or sertraline dose adjustments necessary with concomitant rifampin?
Topics: AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antibiotics, Antitubercular; Antifungal Agen | 2018 |
Cryptococcal meningitis.
Topics: Amphotericin B; Antifungal Agents; Brain; Cryptococcus gattii; Cryptococcus neoformans; Deoxycholic | 2017 |
In vitro antifungal activity of cassia fistula extracts against fluconazole resistant strains of Candida species from HIV patients.
Topics: Antifungal Agents; Candida; Candidiasis; Cassia; Chloroform; Drug Resistance, Fungal; Ethanol; Fluco | 2018 |
Inadequacy of High-Dose Fluconazole Monotherapy Among Cerebrospinal Fluid Cryptococcal Antigen (CrAg)-Positive Human Immunodeficiency Virus-Infected Persons in an Ethiopian CrAg Screening Program.
Topics: Adult; AIDS-Related Opportunistic Infections; Antifungal Agents; Antigens, Fungal; Cryptococcus; Eth | 2017 |
Comparative typing analyses of clinical and environmental strains of the Cryptococcus neoformans/Cryptococcus gattii species complex from Ivory Coast.
Topics: Adult; Amphotericin B; Antifungal Agents; Chloramphenicol; Cote d'Ivoire; Cryptococcosis; Cryptococc | 2018 |
A Prospective Evaluation of a Multisite Cryptococcal Screening and Treatment Program in HIV Clinics in Uganda.
Topics: Adult; Antifungal Agents; Antigens, Fungal; Asymptomatic Diseases; CD4 Lymphocyte Count; Cryptococco | 2018 |
Bilateral Asymptomatic Cryptococcal Retinitis without Choroiditis or Vitritis.
Topics: Administration, Oral; Adult; Amphotericin B; Antifungal Agents; Choroiditis; Cryptococcosis; Cryptoc | 2018 |
A proposal for antifungal epidemiological cut-off values against Histoplasma capsulatum var. capsulatum based on the susceptibility of isolates from HIV-infected patients with disseminated histoplasmosis in Northeast Brazil.
Topics: Amphotericin B; Antifungal Agents; Brazil; Caspofungin; Echinocandins; Fluconazole; Histoplasma; His | 2018 |
Antifungal Activity, Gas Chromatographic-Mass Spectrometric Analysis And in silico Study of Punica Granatum Peel Extracts Against Fluconazole Resistant Strains of Candida Species.
Topics: Antifungal Agents; Candida; Drug Resistance, Fungal; Fluconazole; Fruit; Gas Chromatography-Mass Spe | 2018 |
Drug susceptibility in emerging fungal infections: tests with fluconazole, itraconazole, and amphotericin B.
Topics: Adult; Aged; Amphotericin B; Antifungal Agents; Drug Resistance, Fungal; Female; Fluconazole; Fungi; | 2018 |
Iranian HIV/AIDS patients with oropharyngeal candidiasis: identification, prevalence and antifungal susceptibility of Candida species.
Topics: Adolescent; Adult; Aged; Amphotericin B; Antifungal Agents; Candida albicans; Candidiasis, Oral; Cas | 2018 |
Oral colonization by Candida species in HIV-positive patients: association and antifungal susceptibility study.
Topics: Adult; Antifungal Agents; Brazil; Candida; Candidiasis, Oral; Drug Resistance, Fungal; Female; Fluco | 2018 |
Ischemic stroke as a complication of cryptococcal meningitis and immune reconstitution inflammatory syndrome: a case report.
Topics: Adult; AIDS-Related Opportunistic Infections; Antifungal Agents; Brain Ischemia; Cryptococcus neofor | 2018 |
Laboratory-Reflex Cryptococcal Antigen Screening Is Associated With a Survival Benefit in Tanzania.
Topics: Adult; AIDS-Related Opportunistic Infections; Antifungal Agents; Antigens, Fungal; Female; Fluconazo | 2019 |
Updating guidance for preventing and treating cryptococcal disease: how evidence and decisions interface.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Amphotericin B; Anti-HIV Agents; Antifungal Agents; Anti | 2018 |
[Factors related to oral candidiasis in HIV children and adolescents, species characterization and antifungal susceptibility].
Topics: Adolescent; Adult; AIDS-Related Opportunistic Infections; Antifungal Agents; Candida albicans; Candi | 2018 |
Rare presentation of cutaneous cryptococcosis in advanced HIV.
Topics: Administration, Oral; AIDS-Related Opportunistic Infections; Antifungal Agents; Cryptococcosis; Cryp | 2018 |
Invasive fungal infection by Cryptococcus neoformans var. grubii with bone marrow and meningeal involvement in a HIV-infected patient: a case report.
Topics: Acute Kidney Injury; Amphotericin B; Antifungal Agents; Bone Marrow; CD4-Positive T-Lymphocytes; Cer | 2019 |
A rapidly regressive esophageal squamous papilloma.
Topics: Anti-HIV Agents; Antifungal Agents; Candidiasis; Esophageal Diseases; Esophageal Neoplasms; Fluconaz | 2019 |
Fluconazole plus flucytosine is a good alternative therapy for non-HIV and non-transplant-associated cryptococcal meningitis: A retrospective cohort study.
Topics: Adult; Amphotericin B; Antifungal Agents; Cryptococcus; Deoxycholic Acid; Drug Combinations; Drug Th | 2019 |
Immune reconstitution inflammatory syndrome in an HIV-infected patient with disseminated coccidioidomycosis.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antifungal Agents; Antiretroviral The | 2019 |
Cryptococcal-related Mortality Despite Fluconazole Preemptive Treatment in a Cryptococcal Antigen Screen-and-Treat Program.
Topics: Antigens, Fungal; CD4 Lymphocyte Count; Cohort Studies; Cryptococcus; Fluconazole; HIV Infections; H | 2020 |
Epidemiology and antifungal susceptibility testing of non-albicansCandida species colonizing mucosae of HIV-infected patients in Yaoundé (Cameroon).
Topics: Adolescent; Adult; Aged; Antifungal Agents; Cameroon; Candida; Candida glabrata; Candida tropicalis; | 2019 |
Approaches to antifungal therapies and their effectiveness among patients with cryptococcosis.
Topics: Adult; AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Cryptococcosis; Dru | 2013 |
Treating cryptococcal meningitis in people with HIV.
Topics: AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Drug Therapy, Combination; | 2013 |
Azole susceptibility and resistance in Candida isolates from oral candidiasis and oral colonization in HIV positive patients.
Topics: Candida; Candidiasis, Oral; Drug Resistance, Fungal; Fluconazole; HIV Infections; Humans; Itraconazo | 2011 |
A prospective longitudinal study of the clinical outcomes from cryptococcal meningitis following treatment induction with 800 mg oral fluconazole in Blantyre, Malawi.
Topics: Adolescent; Adult; Antifungal Agents; Female; Fluconazole; HIV Infections; Humans; Induction Chemoth | 2013 |
Cutaneous candidiasis caused by Candida glabrata in a HIV/AIDS patient.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antifungal Agents; Candida gla | 2013 |
A case of cryptococcal lymphadenitis in an HIV-lnfected woman.
Topics: Adult; Amphotericin B; Antifungal Agents; Biopsy, Fine-Needle; Botswana; Cryptococcus neoformans; Fe | 2014 |
Cryptococcal meningitis management in Tanzania with strict schedule of serial lumber punctures using intravenous tubing sets: an operational research study.
Topics: Administration, Intravenous; Adult; Antifungal Agents; Disease Management; Female; Fluconazole; HIV | 2014 |
Dynamic analysis of oral Candida carriage, distribution, and antifungal susceptibility in HIV-infected patients during the first year of highly active antiretroviral therapy in Guangxi, China.
Topics: Adult; Aged; AIDS-Related Opportunistic Infections; Antifungal Agents; Antiretroviral Therapy, Highl | 2014 |
Complicated and protracted cryptococcal disease in HIV-infected children.
Topics: Adolescent; Age Distribution; Amphotericin B; Antifungal Agents; CD4 Lymphocyte Count; Child; Crypto | 2015 |
Clinical and virological response to antiretroviral drugs among HIV patients on first-line treatment in Dar-es-Salaam, Tanzania.
Topics: AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cross | 2014 |
Sub-inhibitory concentrations of antifungals suppress hemolysin activity of oral Candida albicans and Candida tropicalis isolates from HIV-infected individuals.
Topics: Amphotericin B; Antifungal Agents; Candida albicans; Candida tropicalis; Candidiasis, Oral; Fluconaz | 2014 |
Multicenter study of trimethoprim/sulfamethoxazole-related hepatotoxicity: incidence and associated factors among HIV-infected patients treated for Pneumocystis jirovecii pneumonia.
Topics: Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Anti-Infective Agents; Arylamine N-Acetyltransferas | 2014 |
Cryptoccocal meningitis in Yaoundé (Cameroon) HIV infected patients: Diagnosis, frequency and Cryptococcus neoformans isolates susceptibility study to fluconazole.
Topics: Adult; Aged; AIDS-Related Opportunistic Infections; Animals; Antifungal Agents; Birds; Cameroon; Cry | 2015 |
Cryptococcal meningoencephalitis relapse after an eight-year delay: an interplay of infection and immune reconstitution.
Topics: AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antifungal Agents; Antiretroviral Therapy, H | 2015 |
Neuroimaging of HIV-associated cryptococcal meningitis: comparison of magnetic resonance imaging findings in patients with and without immune reconstitution.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antifungal Agents; Antiretroviral The | 2016 |
Influence of sustained low-efficiency diafiltration (SLED-f) on interstitial fluid concentrations of fluconazole in a critically ill patient: Use of microdialysis.
Topics: Adult; Antifungal Agents; Chromatography; Critical Illness; Extracellular Fluid; Fluconazole; HIV In | 2015 |
Overexpression and mutation as a genetic mechanism of fluconazole resistance in Candida albicans isolated from human immunodeficiency virus patients in Indonesia.
Topics: Antifungal Agents; Candida albicans; Candidiasis; Drug Resistance, Fungal; Fluconazole; Fungal Prote | 2015 |
Six-month outcomes of HIV-infected patients given short-course fluconazole therapy for asymptomatic cryptococcal antigenemia.
Topics: Adult; Antifungal Agents; Asymptomatic Diseases; Cryptococcosis; Female; Fluconazole; HIV Infections | 2015 |
Susceptibility profile and epidemiological cut-off values of Cryptococcus neoformans species complex from Argentina.
Topics: AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Argentina; Cryptococcosis; | 2016 |
Cryptococcemia in primary HIV infection.
Topics: Adult; AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Cryptococcosis; Cry | 2016 |
Etiologic Agents and Antifungal Susceptibility of Oral Candidosis from Romanian patients with HIV-infection or type 1 diabetes mellitus.
Topics: Antifungal Agents; Candida; Candidiasis, Oral; Diabetes Complications; Diabetes Mellitus, Type 1; Dr | 2016 |
Species distribution & antifungal susceptibility pattern of oropharyngeal Candida isolates from human immunodeficiency virus infected individuals.
Topics: Adolescent; Adult; Aged; Antiretroviral Therapy, Highly Active; Candida; Candidiasis; Child; Child, | 2016 |
Challenges in the development of novel anticryptococcal agents.
Topics: Amphotericin B; Antifungal Agents; Cryptococcosis; Cryptococcus; Fluconazole; HIV Infections; Humans | 2016 |
[A pediatric case of HIV who diagnosed by virtue of disseminated cryptococcus infection].
Topics: AIDS-Related Opportunistic Infections; Amphotericin B; Anti-Retroviral Agents; Antifungal Agents; Ch | 2016 |
[Fluconazole 1200mg or 800mg for cryptococcal meningitis treatment in Ivory Coast].
Topics: Adult; AIDS-Related Opportunistic Infections; Antifungal Agents; Cote d'Ivoire; Dose-Response Relati | 2017 |
Fungicidal efficacy of various honeys against fluconazole-resistant Candida species isolated from HIV
Topics: AIDS-Related Opportunistic Infections; Antifungal Agents; Candida; Candida albicans; Candida glabrat | 2017 |
Significance of isolation and drug susceptibility testing of non-Candida albicans species causing oropharyngeal candidiasis in HIV patients.
Topics: AIDS-Related Opportunistic Infections; Antifungal Agents; Candida; Candidiasis, Oral; Drug Resistanc | 2008 |
Candida fermentati from HIV patients in Chennai, South India.
Topics: Adult; AIDS-Related Opportunistic Infections; Antifungal Agents; Candida; Candidiasis, Oral; Female; | 2008 |
Development of a sufficient design for estimation of fluconazole pharmacokinetics in people with HIV infection.
Topics: Anti-HIV Agents; Clinical Trials as Topic; Computer Simulation; Cost-Benefit Analysis; Data Interpre | 2008 |
Double-blind active-control trials: beware the comparator you keep.
Topics: Amphotericin B; Antifungal Agents; Candidiasis; Caspofungin; Double-Blind Method; Echinocandins; Fev | 2008 |
Regression of HIV-related diffuse large B-cell lymphoma in response to antiviral therapy alone.
Topics: Adenine; Anti-HIV Agents; Antifungal Agents; Antiretroviral Therapy, Highly Active; Deoxycytidine; D | 2008 |
[A case of acquired encephalopathy in a child. A cause that we thought had disappeared].
Topics: AIDS Dementia Complex; Anti-HIV Agents; Anti-Infective Agents; Drug Therapy, Combination; Female; Fl | 2008 |
HIV-associated extrapulmonary tuberculosis in Thailand: epidemiology and risk factors for death.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Anti-Infective Agents; Cohort Studies | 2009 |
Burden of cryptococcal meningitis in Malawi.
Topics: AIDS-Related Opportunistic Infections; Antifungal Agents; Cryptococcus neoformans; Fluconazole; HIV | 2009 |
Fluconazole resistant opportunistic oro-pharyngeal Candida and non-Candida yeast-like isolates from HIV infected patients attending ARV clinics in Lagos, Nigeria.
Topics: Adolescent; Adult; Aged; AIDS-Related Opportunistic Infections; Antifungal Agents; Candida; Candidia | 2008 |
In vitro activity of voriconazole against Mexican oral yeast isolates.
Topics: Adult; Antifungal Agents; Candida; Candidiasis, Oral; Fluconazole; HIV Infections; Humans; Mexico; M | 2010 |
Amphotericin B plus fluconazole for HIV-associated cryptococcal meningitis.
Topics: Amphotericin B; Antifungal Agents; Clinical Trials as Topic; Fluconazole; HIV Infections; Humans; Me | 2009 |
Effect of high-dose fluconazole on QT interval in patients with human immunodeficiency virus (HIV)-associated cryptococcal meningitis.
Topics: Antifungal Agents; Fluconazole; Heart Conduction System; HIV Infections; Humans; Meningitis, Cryptoc | 2009 |
Effects of antifungal agents in sap activity of Candida albicans isolates.
Topics: Antifungal Agents; Aspartic Acid Proteases; Candida albicans; Candidiasis; Culture Media; DNA, Funga | 2010 |
Longitudinal genotyping of Candida dubliniensis isolates reveals strain maintenance, microevolution, and the emergence of itraconazole resistance.
Topics: Adult; Antifungal Agents; Candida; Candidiasis; DNA Fingerprinting; DNA, Fungal; Drug Resistance, Fu | 2010 |
Oropharyngeal colonization of HIV-infected outpatients in Taiwan by yeast pathogens.
Topics: Adult; Antifungal Agents; Candida; Carrier State; Cohort Studies; Drug Resistance, Fungal; Female; F | 2010 |
Symptomatic relapse of HIV-associated cryptococcal meningitis in South Africa: the role of inadequate secondary prophylaxis.
Topics: Adult; Antifungal Agents; Female; Fluconazole; HIV Infections; Humans; Male; Meningitis, Cryptococca | 2010 |
Cost-effectiveness of serum cryptococcal antigen screening to prevent deaths among HIV-infected persons with a CD4+ cell count < or = 100 cells/microL who start HIV therapy in resource-limited settings.
Topics: Adult; Antifungal Agents; Antigens, Fungal; CD4 Lymphocyte Count; Chemoprevention; Cohort Studies; C | 2010 |
Cost-effectiveness of primary prophylaxis of AIDS associated cryptococcosis in Cambodia.
Topics: AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antifungal Agents; Cambodia; CD4 Lymp | 2010 |
A Case of Cryptococcal Lymphadenitis in an HIV-Infected Child.
Topics: Abdomen; Amphotericin B; Antifungal Agents; Antigens, Fungal; Brain; Child; Cryptococcosis; Cryptoco | 2011 |
Long-term follow-up and survival of antiretroviral-naive patients with cryptococcal meningitis in the pre-antiretroviral therapy era, Gauteng Province, South Africa.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antifungal Agents; Delivery of Health | 2011 |
Oral Candida isolates among HIV-infected subjects in Nigeria.
Topics: Adult; Aged; AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Candida; Cand | 2011 |
A rare, fatal case of invasive spinal aspergillosis in an antiretroviral-naive, HIV-infected man with pre-existing lung colonization.
Topics: Adult; Antifungal Agents; Aspergillus fumigatus; Fatal Outcome; Fluconazole; HIV Infections; Humans; | 2011 |
Difference in virulence between fluconazole-susceptible and fluconazole-resistant Candida albicans in a mouse model.
Topics: Animals; Antifungal Agents; Candida albicans; Candidiasis; Cell Adhesion; Cell Line; Disease Models, | 2011 |
Poor long-term outcomes for cryptococcal meningitis in rural South Africa.
Topics: Adult; Amphotericin B; Antifungal Agents; Female; Fluconazole; HIV Infections; Humans; Male; Meningi | 2011 |
Oropharyngeal yeast colonization in HIV-infected outpatients in southern Taiwan: CD4 count, efavirenz therapy and intravenous drug use matter.
Topics: Adult; AIDS-Related Opportunistic Infections; Alkynes; Anti-HIV Agents; Antifungal Agents; Benzoxazi | 2012 |
Predictors of poor clinical outcome of cryptococcal meningitis in HIV-infected patients.
Topics: Amphotericin B; Antifungal Agents; Cerebrospinal Fluid; Fluconazole; HIV Infections; Humans; Meningi | 2011 |
Coccidioidomycosis of cervical lymph nodes in an HIV-infected patient with immunologic reconstitution on potent HAART: a rare observation in a nonendemic area.
Topics: Antifungal Agents; Antiretroviral Therapy, Highly Active; Coccidioidomycosis; Fluconazole; HIV Infec | 2012 |
An unusual presentation of pulmonary cryptococcosis with co-existing disseminated tuberculosis in an AIDS patient.
Topics: Adult; AIDS-Related Opportunistic Infections; Antifungal Agents; Antitubercular Agents; Cryptococcos | 2012 |
Candida dubliniensis: an appraisal of its clinical significance as a bloodstream pathogen.
Topics: Aged; Aged, 80 and over; Candida; Candidiasis; Child; DNA, Ribosomal; Drug Resistance, Fungal; Femal | 2012 |
Resistance of Asian Cryptococcus neoformans serotype A is confined to few microsatellite genotypes.
Topics: Asia; Cryptococcus neoformans; Drug Resistance, Fungal; Fluconazole; Flucytosine; Genetic Variation; | 2012 |
Role of fluconazole in a case of rapid onset ritonavir and inhaled fluticasone-associated secondary adrenal insufficiency.
Topics: Adrenal Insufficiency; Androstadienes; Anti-HIV Agents; Anti-Inflammatory Agents; Bronchitis; Drug I | 2012 |
Prevalence and antifungal susceptibility of Candida parapsilosis complex isolates collected from oral cavities of HIV-infected individuals.
Topics: Amphotericin B; Antifungal Agents; Candida; Candidiasis, Oral; Caspofungin; Echinocandins; Female; F | 2012 |
Challenges in diagnosis and management of Cryptococcal immune reconstitution inflammatory syndrome (IRIS) in resource limited settings.
Topics: Adult; AIDS-Related Opportunistic Infections; Amphotericin B; Anti-HIV Agents; Antifungal Agents; Cr | 2012 |
Replacement of Candida albicans with C. dubliniensis in human immunodeficiency virus-infected patients with oropharyngeal candidiasis treated with fluconazole.
Topics: AIDS-Related Opportunistic Infections; Antifungal Agents; Candida; Candida albicans; Candidiasis, Or | 2002 |
Prognostic factors for the clinical effectiveness of fluconazole in the treatment of oral candidiasis in HIV-1-infected individuals.
Topics: Adult; Aged; AIDS-Related Opportunistic Infections; Candidiasis, Oral; Female; Fluconazole; HIV Infe | 2002 |
Clinical and mycological responses to fluconazole and fluconazole MIC in oropharyngeal candidiasis in HIV-infected patients.
Topics: Adult; Antifungal Agents; Candida; Candidiasis; Female; Fluconazole; HIV Infections; Humans; Male; M | 2002 |
Point prevalence, microbiology and fluconazole susceptibility patterns of yeast isolates colonizing the oral cavities of HIV-infected patients in the era of highly active antiretroviral therapy.
Topics: Adult; Aged; Antiretroviral Therapy, Highly Active; Candida; Candidiasis, Oral; Drug Resistance, Fun | 2002 |
Relapse of coccidioidomycosis despite immune reconstitution after fluconazole secondary prophylaxis in a patient with AIDS.
Topics: AIDS-Related Opportunistic Infections; Antifungal Agents; Coccidioidomycosis; Drug Therapy, Combinat | 2003 |
Candida albicans switch phenotypes display differential levels of fitness.
Topics: Antifungal Agents; Blotting, Southern; Candida albicans; Candidiasis; Drug Resistance, Fungal; Fluco | 2004 |
[Study of acute vulvovaginitis in sexually active adult women, with special reference to candidosis, in patients of the Francisco J. Muñiz Infectious Diseases Hospital].
Topics: Acute Disease; Adolescent; Adult; Argentina; Candida; Candidiasis, Vulvovaginal; Carrier State; Como | 2004 |
Colonization of human immunodeficiency virus-infected outpatients in Taiwan with Candida species.
Topics: AIDS-Related Opportunistic Infections; Antifungal Agents; Candida; Candidiasis, Oral; Cohort Studies | 2005 |
[Meningeal cryptococcosis as a sign of immune reconstitution syndrome].
Topics: Adult; AIDS-Related Opportunistic Infections; Amphotericin B; Anti-HIV Agents; Antifungal Agents; An | 2005 |
Detection of Candida dubliniensis in oropharyngeal samples of Turkish HIV-positive patients.
Topics: Adult; Aged; Amphotericin B; Antifungal Agents; Candida; Candidiasis, Oral; Female; Fluconazole; HIV | 2005 |
Oral Candida isolates colonizing or infecting human immunodeficiency virus-infected and healthy persons in Mexico.
Topics: Adult; Aged; Aged, 80 and over; Antiretroviral Therapy, Highly Active; Candida; Drug Resistance, Fun | 2005 |
[Clinical cases in medical mycology. Case No. 16].
Topics: Adolescent; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antifungal Agents; Blood Sedimen | 2005 |
Safety and tolerability of nevirapine-based antiretroviral therapy in HIV-infected patients receiving fluconazole for cryptococcal prophylaxis: a retrospective cohort study.
Topics: Adult; Alanine Transaminase; Anti-HIV Agents; Antifungal Agents; Antiretroviral Therapy, Highly Acti | 2005 |
Detection of Candida dubliniensis in Venezuela.
Topics: AIDS-Related Opportunistic Infections; Antifungal Agents; Candida; Candida albicans; Candidiasis, Or | 2005 |
Fluconazole prophylaxis in HIV disease, revisited.
Topics: Antifungal Agents; Candidiasis, Oral; Drug Resistance, Fungal; Fluconazole; HIV Infections; Humans | 2005 |
Prenatal exposure to fluconazole: an identifiable dysmorphic phenotype.
Topics: Abnormalities, Drug-Induced; Abnormalities, Multiple; Antifungal Agents; Female; Fluconazole; HIV In | 2005 |
Cryptococcosis in human immunodeficiency virus-negative patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amphotericin B; Antifungal Agents; Cryptococcosis; Crypt | 2006 |
Oral epithelial cell antifungal activity: approaches to evaluate a broad range of clinical conditions.
Topics: AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Candida; Candidiasis, Oral | 2005 |
Phenotypic and genotypic evaluation of fluconazole resistance in vaginal Candida strains isolated from HIV-infected women from Brazil.
Topics: Adult; AIDS-Related Opportunistic Infections; Antifungal Agents; Brazil; Candida; Candidiasis, Vulvo | 2005 |
Molecular epidemiology of long-term colonization of Candida albicans strains from HIV-infected patients.
Topics: Adult; Antifungal Agents; Candida albicans; Candidiasis, Oral; DNA Fingerprinting; Drug Resistance, | 2006 |
Fluconazole-resistant pseudomembranous oral candidiasis.
Topics: Adult; Amphotericin B; Antifungal Agents; Candidiasis, Oral; Drug Resistance, Fungal; Female; Flucon | 2006 |
Ritonavir-dependent fluconazole boosting of nelfinavir: a report of three cases.
Topics: Adult; Antifungal Agents; Drug Synergism; Drug Therapy, Combination; Fluconazole; HIV Infections; HI | 2006 |
Results obtained with various antifungal susceptibility testing methods do not predict early clinical outcome in patients with cryptococcosis.
Topics: AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Cryptococcosis; Cryptococc | 2006 |
Successful treatment of Candida parapsilosis (fluconazole-resistant) osteomyelitis with caspofungin in a HIV patient.
Topics: Candida; Candidiasis; Caspofungin; Drug Resistance, Microbial; Echinocandins; Fluconazole; HIV; HIV | 2006 |
Plasma nevirapine levels, adverse events and efficacy of antiretroviral therapy among HIV-infected patients concurrently receiving nevirapine-based antiretroviral therapy and fluconazole.
Topics: Anti-HIV Agents; Antifungal Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Dru | 2007 |
Exacerbated inflammatory reaction to Trichophyton rubrum infection on an HIV-positive patient successfully treated with fluconazole.
Topics: Adult; AIDS-Related Opportunistic Infections; Antifungal Agents; Female; Fluconazole; HIV Infections | 2007 |
Acquired resistance to echinocandins in Candida albicans: case report and review.
Topics: Adult; Amino Acid Sequence; Amino Acid Substitution; Amphotericin B; Antifungal Agents; Candida albi | 2007 |
Fungal burden, early fungicidal activity, and outcome in cryptococcal meningitis in antiretroviral-naive or antiretroviral-experienced patients treated with amphotericin B or fluconazole.
Topics: Adult; AIDS-Related Opportunistic Infections; Amphotericin B; Anti-Retroviral Agents; Drug Therapy, | 2007 |
Correlation of the MIC and dose/MIC ratio of fluconazole to the therapeutic response of patients with mucosal candidiasis and candidemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antifungal Agents; Area Under Curve; Candida; Candidiasi | 2007 |
Drug-drug interactions with systemic antifungals in clinical practice.
Topics: Adult; Aged; Amphotericin B; Antifungal Agents; Creatinine; Cyclosporine; Drug Interactions; Female; | 2007 |
Molluscum or a mimic? Add Penicillium marneffei!
Topics: Antifungal Agents; Antigens, Fungal; Antiretroviral Therapy, Highly Active; Cryptococcosis; Fluconaz | 2007 |
Survival time of HIV-infected patients with cryptococcal meningitis.
Topics: Adult; Amphotericin B; Anti-Bacterial Agents; CD4 Lymphocyte Count; Comorbidity; Female; Fluconazole | 2007 |
Cryptococcosis masquerading as a tuboovarian abscess.
Topics: Abscess; Adult; Antifungal Agents; Cryptococcosis; Cystadenocarcinoma, Mucinous; Diagnosis, Differen | 2008 |
Antifungal susceptibility testing of micafungin against Candida glabrata isolates.
Topics: Antifungal Agents; Candida glabrata; Drug Resistance, Fungal; Echinocandins; Fluconazole; Head and N | 2008 |
The impact of primary prophylaxis for cryptococcosis on fluconazole resistance in Candida species.
Topics: AIDS-Related Opportunistic Infections; Candida; Cryptococcosis; Drug Resistance, Fungal; Fluconazole | 2008 |
Pharmacokinetics and bioavailability of fluconazole in two groups of males with human immunodeficiency virus (HIV) infection compared with those in a group of males without HIV infection.
Topics: Administration, Oral; Adolescent; Adult; Biological Availability; CD4 Lymphocyte Count; Fluconazole; | 1995 |
Fulminant cryptococcal infections in HIV-infected patients on oral fluconazole.
Topics: Administration, Oral; Adult; AIDS-Related Opportunistic Infections; Candidiasis, Oral; Cryptococcosi | 1995 |
High-performance liquid chromatographic determination of the antifungal drug fluconazole in plasma and saliva of human immunodeficiency virus-infected patients.
Topics: Calibration; Chromatography, High Pressure Liquid; Fluconazole; HIV Infections; Humans; Saliva; Spec | 1995 |
Primary prevention of cryptococcal meningitis by fluconazole in HIV-infected patients.
Topics: Adult; Case-Control Studies; CD4 Lymphocyte Count; Female; Fluconazole; HIV Infections; Humans; Male | 1995 |
CD4+ counts before and after switching to monoclonal high-purity factor VIII concentrate in HIV-infected haemophilic patients.
Topics: Adolescent; Adult; Aged; AIDS-Related Opportunistic Infections; CD4 Lymphocyte Count; Child; Child, | 1994 |
[Adherence of isolated Candida albicans strains from HIV+ infected patients to buccal epithelial cells: correlation with serotype, sensitivity to fluconazole and virulence].
Topics: AIDS-Related Opportunistic Infections; Bacterial Adhesion; Candida albicans; Candidiasis; Fluconazol | 1994 |
[Treatment and prevention of main infections associated with HIV].
Topics: Adrenal Cortex Hormones; Amphotericin B; Controlled Clinical Trials as Topic; Cryptococcosis; Flucon | 1994 |
In vitro activity of itraconazole against fluconazole-susceptible and -resistant Candida albicans isolates from oral cavities of patients infected with human immunodeficiency virus.
Topics: Candida albicans; Drug Resistance, Microbial; Fluconazole; HIV Infections; Humans; Itraconazole; Mic | 1994 |
Logarithmic relationship of the CD4 count to survival in patients with human immunodeficiency virus infection.
Topics: Acquired Immunodeficiency Syndrome; Adult; Age Factors; AIDS-Related Opportunistic Infections; CD4-P | 1993 |
[Esophageal mycosis during primary human immunodeficiency virus infection].
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Candidiasis; Fluco | 1993 |
Therapy for oropharyngeal candidiasis in HIV-infected patients.
Topics: AIDS-Related Opportunistic Infections; Candidiasis, Oral; Clotrimazole; Fluconazole; HIV Infections; | 1993 |
Fluconazole-induced toxic epidermal necrolysis in a patient with human immunodeficiency virus infection.
Topics: Adult; AIDS-Related Opportunistic Infections; Candidiasis, Oral; Fluconazole; HIV Infections; Humans | 1993 |
Weekly fluconazole for the suppression of recurrent thrush in HIV-seropositive patients: impact on the incidence of disseminated cryptococcal infection.
Topics: Adult; Antifungal Agents; Candidiasis, Oral; Cryptococcosis; Female; Fluconazole; HIV Infections; Hu | 1995 |
Torulopsis glabrata: azole susceptibilities by microdilution colorimetric and macrodilution broth assays.
Topics: Antifungal Agents; Candida; Candidiasis; Colorimetry; Dose-Response Relationship, Drug; Fluconazole; | 1995 |
Correlation between in vitro resistance to fluconazole and clinical outcome of oropharyngeal candidiasis in HIV-infected patients.
Topics: Antifungal Agents; Candida albicans; Candidiasis, Oral; Drug Resistance, Microbial; Female; Fluconaz | 1996 |
Thrombocytopenia caused by fluconazole.
Topics: Antifungal Agents; Fluconazole; HIV Infections; Humans; Onychomycosis; Thrombocytopenia | 1996 |
Pharmacokinetics of fluconazole in people with HIV infection: a population analysis.
Topics: Adult; Antifungal Agents; Fluconazole; HIV Infections; Humans; Male; Middle Aged; Population Dynamic | 1996 |
[Itraconazole suspension in the treatment of HIV-infected patients with fluconazole-resistant oropharyngeal candidiasis and esophagitis].
Topics: AIDS-Related Opportunistic Infections; Antifungal Agents; Candida; Candida albicans; Candidiasis; Ca | 1996 |
Oropharyngeal yeast flora and fluconazole resistance in HIV-infected patients receiving long-term continuous versus intermittent fluconazole therapy.
Topics: Adult; Aged; Antifungal Agents; Candida albicans; Candidiasis, Oral; Case-Control Studies; Drug Admi | 1996 |
Relationship between fluconazole dosage regimens and the emergence of fluconazole-resistant Candida albicans.
Topics: Antifungal Agents; Candida albicans; Candidiasis, Oral; Drug Resistance, Microbial; Fluconazole; HIV | 1996 |
[Focusing on therapy of systemic mycoses].
Topics: AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Candidiasis; Dose-Response | 1995 |
Itraconazole cyclodextrin solution: the role of in vitro susceptibility testing in predicting successful treatment of HIV-related fluconazole-resistant and fluconazole-susceptible oral candidosis.
Topics: Antifungal Agents; Candida; Candidiasis, Oral; CD4 Lymphocyte Count; Drug Resistance, Microbial; Flu | 1997 |
In vitro activities of voriconazole (UK-109,496) against fluconazole-susceptible and -resistant Candida albicans isolates from oral cavities of patients with human immunodeficiency virus infection.
Topics: Antifungal Agents; Candida albicans; Candidiasis, Oral; Drug Resistance, Microbial; Fluconazole; HIV | 1997 |
Antifungal drug susceptibilities of oral Candida dubliniensis isolates from human immunodeficiency virus (HIV)-infected and non-HIV-infected subjects and generation of stable fluconazole-resistant derivatives in vitro.
Topics: Antifungal Agents; Candida; Candidiasis, Oral; DNA Fingerprinting; DNA, Fungal; Drug Resistance, Mic | 1997 |
Evaluation of the E test for fluconazole susceptibility testing of Candida albicans isolates from oropharyngeal candidiasis.
Topics: Amphotericin B; Antifungal Agents; Candida albicans; Candidiasis, Oral; CD4 Lymphocyte Count; Flucon | 1997 |
[Comparison of three antifungal susceptibility testing methods for the in vitro testing of Candida isolates from patients with HIV infection].
Topics: AIDS-Related Opportunistic Infections; Antifungal Agents; Candida; Candida albicans; Candidiasis; Dr | 1996 |
Point prevalence of oropharyngeal carriage of fluconazole-resistant Candida in human immunodeficiency virus-infected patients.
Topics: Adult; Antifungal Agents; Candida; Candidiasis, Oral; Carrier State; CD4 Lymphocyte Count; Drug Resi | 1997 |
Stable azole drug resistance associated with a substrain of Candida albicans from an HIV-infected patient.
Topics: AIDS-Related Opportunistic Infections; Antifungal Agents; Azoles; Candida albicans; Candidiasis, Ora | 1997 |
Fluconazole resistant oral candidiasis in HIV-infected patients.
Topics: AIDS-Related Opportunistic Infections; Antifungal Agents; Candida; Candidiasis, Oral; Case-Control S | 1997 |
[Pulmonary cryptococcosis during HIV infection. 15 cases].
Topics: Adult; AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Cryptococcosis; Flu | 1997 |
Cryptococcosis, epileptic seizures and encephalopathy in a HIV-infected patient.
Topics: Administration, Oral; Adult; AIDS-Related Opportunistic Infections; Amphotericin B; Cryptococcus neo | 1997 |
Resolution of azole-resistant oropharyngeal candidiasis after initiation of potent combination antiretroviral therapy.
Topics: AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antifungal Agents; Candidiasis, Oral; Drug R | 1998 |
Detection of Candida dubliniensis in oropharyngeal samples from human immunodeficiency virus-infected patients in North America by primary CHROMagar candida screening and susceptibility testing of isolates.
Topics: AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Candida; Candidiasis, Oral | 1998 |
Distinct patterns of gene expression associated with development of fluconazole resistance in serial candida albicans isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis.
Topics: Antifungal Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Candida albicans; Candid | 1998 |
Withdrawal of fluconazole suppressive therapy for thrush in patients responding to combination antiviral therapy including protease inhibitors.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antifungal Agents; Candidiasis, Oral; | 1998 |
Indinavir-fluconazole interaction.
Topics: AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antifungal Agents; Drug Interactions; Flucon | 1999 |
[Epidemiology of yeast colonization and oropharyngeal infection other than Candida albicans in patients with HIV infection].
Topics: Adult; Aged; Candida; Candidiasis; Female; Fluconazole; HIV Infections; Humans; Male; Microbial Sens | 1999 |
Multiple resistant phenotypes of Candida albicans coexist during episodes of oropharyngeal candidiasis in human immunodeficiency virus-infected patients.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Candida albicans; Candidiasis; Candidiasis, | 1999 |
Clonal and spontaneous origins of fluconazole resistance in Candida albicans.
Topics: AIDS-Related Opportunistic Infections; Antifungal Agents; Candida albicans; Candidiasis; Candidiasis | 2000 |
Discontinuation of secondary prophylaxis for cryptococcal meningitis in HIV-infected patients responding to highly active antiretroviral therapy.
Topics: Adult; AIDS-Related Opportunistic Infections; Antifungal Agents; Antiretroviral Therapy, Highly Acti | 2000 |
Clearance of a fluconazole-resistant Candida albicans strain after switching antifungal therapy and initiation of triple therapy for HIV infection.
Topics: Adult; AIDS-Related Opportunistic Infections; Antifungal Agents; Antiretroviral Therapy, Highly Acti | 2000 |
CTG studies yield results. AIDS Clinical Trials Group.
Topics: Acyclovir; Child; Clinical Trials as Topic; Cytomegalovirus Infections; Didanosine; Drug Therapy, Co | 1995 |
CTG studies yield results. AIDS Clinical Trials Group.
Topics: Acyclovir; Child; Clinical Trials as Topic; Cytomegalovirus Infections; Didanosine; Drug Therapy, Co | 1995 |
CTG studies yield results. AIDS Clinical Trials Group.
Topics: Acyclovir; Child; Clinical Trials as Topic; Cytomegalovirus Infections; Didanosine; Drug Therapy, Co | 1995 |
CTG studies yield results. AIDS Clinical Trials Group.
Topics: Acyclovir; Child; Clinical Trials as Topic; Cytomegalovirus Infections; Didanosine; Drug Therapy, Co | 1995 |
CTG studies yield results. AIDS Clinical Trials Group.
Topics: Acyclovir; Child; Clinical Trials as Topic; Cytomegalovirus Infections; Didanosine; Drug Therapy, Co | 1995 |
CTG studies yield results. AIDS Clinical Trials Group.
Topics: Acyclovir; Child; Clinical Trials as Topic; Cytomegalovirus Infections; Didanosine; Drug Therapy, Co | 1995 |
CTG studies yield results. AIDS Clinical Trials Group.
Topics: Acyclovir; Child; Clinical Trials as Topic; Cytomegalovirus Infections; Didanosine; Drug Therapy, Co | 1995 |
CTG studies yield results. AIDS Clinical Trials Group.
Topics: Acyclovir; Child; Clinical Trials as Topic; Cytomegalovirus Infections; Didanosine; Drug Therapy, Co | 1995 |
CTG studies yield results. AIDS Clinical Trials Group.
Topics: Acyclovir; Child; Clinical Trials as Topic; Cytomegalovirus Infections; Didanosine; Drug Therapy, Co | 1995 |
Abnormal cryptococcal serology in an asymptomatic patient.
Topics: Adult; AIDS-Related Opportunistic Infections; Antigens, Fungal; CD4 Lymphocyte Count; Cryptococcosis | 1995 |
First women's HIV conference hears go-for-broke antiretroviral strategy.
Topics: Antifungal Agents; Antiviral Agents; CD4 Lymphocyte Count; Counseling; Female; Fluconazole; Health E | 1995 |
Opportunistic infections update.
Topics: AIDS-Related Opportunistic Infections; DNA, Viral; Fluconazole; HIV Infections; HIV-1; Humans; Mycob | 1996 |
Coccidioidomycosis.
Topics: Amphotericin B; Antifungal Agents; Coccidioides; Coccidioidomycosis; Fluconazole; HIV Infections; Hu | 1997 |
Heterogeneity in antifungal susceptibility of clones of Candida albicans isolated on single and sequential visits from a HIV-infected southern Chinese cohort.
Topics: Adult; AIDS-Related Opportunistic Infections; Amphotericin B; Analysis of Variance; Antifungal Agent | 2001 |
Post-antifungal effect of polyene, azole and DNA-analogue agents against oral Candida albicans and Candida tropicalis isolates in HIV disease.
Topics: AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Candida; Candida albicans; | 2001 |
Salivary anticandidal activity and saliva composition in an HIV-infected cohort.
Topics: Adult; Antifungal Agents; Candida albicans; Candidiasis, Oral; Case-Control Studies; Cohort Studies; | 2001 |
Prevalence of molecular mechanisms of resistance to azole antifungal agents in Candida albicans strains displaying high-level fluconazole resistance isolated from human immunodeficiency virus-infected patients.
Topics: Antifungal Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Azoles; Candida albicans | 2001 |
Possible interaction between gliclazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia.
Topics: Anti-Infective Agents; Antifungal Agents; Diabetes Complications; Diabetes Mellitus; Drug Interactio | 2001 |
Candida dubliniensis candidaemia in an HIV-positive patient in Ireland.
Topics: Adult; Antifungal Agents; Candida; Candidiasis; DNA, Fungal; Fatal Outcome; Fluconazole; Fungemia; H | 2002 |
Genotyping and antifungal susceptibility of human subgingival Candida albicans isolates.
Topics: Adult; Amphotericin B; Antifungal Agents; Candida albicans; Dental Plaque; DNA, Fungal; Drug Resista | 2002 |
Identification of Candida dubliniensis among oral yeast isolates from an Italian population of human immunodeficiency virus-infected (HIV+) subjects.
Topics: Adult; Agar; Antifungal Agents; Candida; Candida albicans; Candidiasis, Oral; Chromogenic Compounds; | 2002 |
In vitro activities of terbinafine in combination with fluconazole, itraconazole, voriconazole, and posaconazole against clinical isolates of Candida glabrata with decreased susceptibility to azoles.
Topics: Antifungal Agents; Azoles; Candida; Dose-Response Relationship, Drug; Fluconazole; HIV Infections; H | 2002 |
Molecular mechanisms of fluconazole resistance in Candida dubliniensis isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis.
Topics: Amino Acid Sequence; Antifungal Agents; ATP-Binding Cassette Transporters; Blotting, Northern; Candi | 2002 |
[Desensitization to fluconazole in patient with human inmunodeficiency virus infection].
Topics: Adult; Antifungal Agents; Cryptococcosis; Drug Resistance, Fungal; Fluconazole; HIV Infections; Huma | 2002 |
Primary prophylaxis with fluconazole against systemic fungal infections in HIV-positive patients.
Topics: Adult; CD4-Positive T-Lymphocytes; Female; Fluconazole; Follow-Up Studies; HIV Infections; Humans; L | 1992 |
Reduced azole susceptibility of oral isolates of Candida albicans from HIV-positive patients and a derivative exhibiting colony morphology variation.
Topics: Candida albicans; Candidiasis, Oral; DNA, Fungal; Fluconazole; HIV Infections; Humans; Ketoconazole; | 1992 |
Clinical, endoscopic, immunologic, and therapeutic aspects of oropharyngeal and esophageal candidiasis in HIV-infected patients: a survey of 114 cases.
Topics: Biopsy; Candidiasis; Candidiasis, Oral; CD4-CD8 Ratio; Drug Administration Schedule; Esophagitis; Es | 1992 |
Candidal mitral endocarditis and long-term treatment with fluconazole in a patient with human immunodeficiency virus infection.
Topics: Adult; Candidiasis; Endocarditis; Female; Fluconazole; HIV Infections; Humans | 1992 |
Does fluconazole prevent cryptococcal meningitis in human immunodeficiency virus-infected patients?
Topics: Adult; Case-Control Studies; Fluconazole; HIV Infections; Humans; Male; Meningitis, Cryptococcal; Re | 1992 |
[Fluconazole treatment of cryptococcal meningitis associated with HIV infection. Presentation of 4 cases].
Topics: Administration, Oral; Adult; Amphotericin B; Drug Therapy, Combination; Female; Fluconazole; Flucyto | 1992 |
[Comparative study of the therapy of Candida esophagitis in HIV-1-infected patients with fluconazole or amphotericin B and flucytosine].
Topics: Amphotericin B; Candidiasis; Drug Therapy, Combination; Esophagitis; Female; Fluconazole; Flucytosin | 1991 |
Gas chromatographic analysis, with electron capture detection, of the antifungal drug fluconazole in microvolumes of human plasma.
Topics: Chromatography, Gas; Electrons; Fluconazole; HIV Infections; Humans; Molecular Structure; Reproducib | 1991 |
Development of histoplasmosis in a human immunodeficiency virus-infected patient receiving fluconazole.
Topics: Cryptococcosis; Fluconazole; Histoplasmosis; HIV Infections; Humans; Male; Meningitis; Middle Aged | 1991 |
[Laboratory's controls of antifungal treatment by the fluconazole of the candidiasis in immunocompromised patients].
Topics: Acquired Immunodeficiency Syndrome; Candida albicans; Candidiasis; Dose-Response Relationship, Drug; | 1991 |
Clinical aspects of HIV and AIDS.
Topics: Acquired Immunodeficiency Syndrome; Fluconazole; Ganciclovir; HIV Infections; Humans; Opportunistic | 1990 |
[Candida esophagitis treated with a single dose of fluconazole in patients with HIV: presentation of 11 cases].
Topics: Adult; Candidiasis; Esophagitis; Female; Fluconazole; HIV Infections; Humans; Male; Prospective Stud | 1990 |
Infectious disease emergencies in persons with HIV/AIDS: an update.
Topics: Acquired Immunodeficiency Syndrome; Amphotericin B; Clindamycin; Communicable Diseases; Fluconazole; | 1990 |
Maintenance therapy of oropharyngeal candidiasis in HIV-infected patients with fluconazole.
Topics: Administration, Oral; Adult; Candidiasis, Oral; Female; Fluconazole; HIV Infections; Humans; Male | 1990 |
Single-dose therapy for esophageal candidiasis with fluconazole.
Topics: Administration, Oral; Adult; Candidiasis; Esophageal Diseases; Female; Fluconazole; HIV Infections; | 1990 |
Fluconazole for ketoconazole-resistant oropharyngeal candidiasis in HIV-1 infected patients.
Topics: Adult; Candidiasis, Oral; Drug Resistance, Microbial; Female; Fluconazole; HIV Infections; HIV-1; Hu | 1990 |